carbapenems has been researched along with Urinary Tract Infections in 227 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.44) | 18.7374 |
| 1990's | 17 (7.49) | 18.2507 |
| 2000's | 30 (13.22) | 29.6817 |
| 2010's | 115 (50.66) | 24.3611 |
| 2020's | 64 (28.19) | 2.80 |
| Authors | Studies |
|---|---|
| Bou, G; Díaz-Regañón, J; Fariñas, MC; Fenoll, R; Ferrer, R; Gómez-Ulloa, D; Lara, N; López, D; Lozano, V; Maseda, E; McCann, E; Salavert, M | 1 |
| Chakraborty, DS; Chatterjee, S; Choudhury, S; Lahiry, S | 1 |
| Bower, C; Jacob, JT; Sexton, ME | 1 |
| Chen, M; Liu, H; Lyu, J; Qiu, S; Xue, L; Yu, G | 1 |
| Neville, LF; Rendell, JT; Shalit, I; Warn, PA | 1 |
| Critchley, IA; Dane, A; Eckburg, PB; Jain, A; Keutzer, T; Kwak, H; Melnick, D; Moore, G; Muir, L; Phelan, AM; Talley, AK; Walpole, S | 1 |
| Becerra-Aparicio, F; Fuchs, F; Higgins, PG; Seifert, H; Xanthopoulou, K | 1 |
| Kleppisch, M; Preisendörfer, B; Rauchensteiner, S; Schweizer, C; Seiffert, A; Wilke, MH | 1 |
| Bezruk, VV; Bulyk, TS; Buriak, OH; Godovanets, OS; Honcharuk, LM; Hresko, MD; Hresko, MM; Makarova, OV; Pervozvanska, OI; Rynzhuk, LV; Sheremet, MI; Shkrobanets, ID; Velia, MI; Voytkevich, NI; Yurkiv, OI; Yurniuk, SV | 1 |
| Bonnin, RA; Creton, E; Dortet, L; Emeraud, C; Girlich, D; Godmer, A; Jousset, AB; Mahamdi, F; Naas, T; Vanparis, O | 1 |
| Rosellen, J; Wagenlehner, F | 1 |
| Courtois, R; Danneels, P; Dubée, V; Eveillard, M; Kempf, M; Mahieu, R; Quinqueneau, C; Rihet, C; Vannier, C | 1 |
| Alfandari, S; Bajolet, O; Blanchard, H; Colomb-Cotinat, M; Daniau, C; Dumartin, C; Lecuru, M; Simon, L | 1 |
| Giovannenze, F; Murri, R; Rando, E; Sacco, E | 1 |
| Ahmed, D; Amin, MB; Asaduzzaman, M; Hossain, MI; Islam, MA; Islam, MR; Khan, R; Rahman, M; Riley, LW | 1 |
| Castanheira, M; Cotroneo, N; Critchley, I; Hubler, C; Kantro, V; Kimbrough, JH; Mendes, RE | 1 |
| Alammar, MA; Alotaibi, BS; Bandy, A; Farhana, A; Mohammed, AH; Shah, NN; Tantry, BA; Wani, F | 1 |
| Armaki, MT; Gholinia, H; Halaji, M; Hosseini, A; Nasrollahian, S; Pournajaf, A; Rajabnia, M; Teimourian, M | 1 |
| Abduljabbar Jaloob Aljanaby, A; Abduljabbar Jaloob Aljanaby, I; Hayder Hasan, T; Yahya Abdulla, N | 1 |
| Guo, S; Li, X; Li, Y; Shao, J; Tian, M; Tong, H; Wei, M; Xu, B; Yan, B | 1 |
| Aysert-Yildiz, P; Dizbay, M; Habibi, H; Özgen-Top, Ö | 1 |
| Chen, H; Jiang, Y; Shen, L; Wu, H | 1 |
| A Katouah, H; Acker, M; Al Hadi, R; Ali, M; Alserihi, R; Alyami, J; Alzahrani, E; Amirazodi, M; Amrillah, T; Andreassen, OA; Ardiccioni, C; Ask, H; Atzori, C; Ayorech, Z; Azambuja, JH; Azmi, R; Badem, S; Balci, AB; Bali, H; Baranova, NS; Barantsevich, ER; Barocci, S; Bauer, RJ; Bauermeister, JA; Bazhenova, TA; Biagetti, G; Bigdeli, F; Bonar, EE; Bouloumis, T; Bu, Y; Cai, Z; Cakiroglu, B; Canetto, SS; Cao, J; Caucci, S; Cerbo, I; Chen, C; Chen, J; Chen, Q; Chen, Y; Cheng, B; Cheng, X; Chinappi, M; Choya, A; Cicconardi, F; Cipolletta, S; Colasurdo, G; Costabile, BK; Coughlin, LN; Crippa, P; D'Agostino, M; D'Annessa, I; Daryanoosh, F; Das, R; Davey Smith, G; Davidson, BR; Davies, NM; Davis, TME; Davis, WA; de Rivas, B; Demir, D; Deng, Z; Dhanya, TM; Di Marino, D; Divya, KM; Dong, N; Drinkwater, JJ; Ekholuenetale, M; El-Bindary, AA; El-Bindary, MA; El-Desouky, MG; Elsayed, H; Ema, K; Endraswari, PD; Entilli, L; Ettl, T; Eyado, A; Fan, X; Fang, W; Farina, M; Florimbio, AR; Fowobaje, KR; Gaeini, A; Gao, XM; Gao, Y; Ghaemi, R; Ghelardi, E; Gilmutdinov, IF; Gochicoa-Rangel, L; Goncu, MT; Gözüküçük, R; Grammatikopoulos, P; Gu, Y; Guan, ZJ; Gucu, A; Guldberg, R; Gungor, O; Guo, W; Gutiérrez-Ortiz, JI; Guzmán-Boulloud, N; Guzmán-Valderrábano, C; Głuszko, A; Hama, A; Hamada, M; Han, J; Hashimoto, T; Havdahl, A; Hayashita, T; He, X; Helgeland, Ø; Hinck, AP; Hinck, CS; Holtzapple, M; Hou, Y; Howe, LD; Hu, B; Hu, H; Huang, L; Huang, Z; Hughes, AM; Hussain, G; Ibidoja, OJ; Ichikawa, D; Imber, C; Islam, MR; Iype, S; Jaber, J; Jacobs, R; Jafry, AT; Ji, L; Ji, X; Jiang, L; Jiang, Y; Jie, HFM; Jie, HM; Johansen, MP; Johansson, S; Juan, LX; Juan, W; Kahraman, N; Kallinger, I; Kang, H; Karakulova, YV; Kärmer, T; Kataoka, S; Kato, K; Kawashima, N; Kazim, AH; Khalil, MR; Kitazawa, H; Klimesova, YM; Kojima, S; Kose, M; Kostakis, ID; Koushkie Jahromi, M; Krishna, GA; Krizova, D; La Teana, A; Lan, K; Li, J; Li, JZ; Li, M; Li, R; Li, S; Li, Y; Li, Z; Liu, H; Liu, J; Liu, KG; Liu, L; Liu, Q; Liu, T; Liu, X; Lomachenko, KA; López-Fonseca, R; Ludwig, N; Luo, A; Luo, L; Luo, Y; Lupetti, A; M El-Metwaly, N; Ma, K; Maemura, R; Magnus, P; Manakin, YV; Mancia, F; Mashood, LO; Matsumoto, K; Mehrabi, A; Meier, JK; Mekonnen, Y; Mencarelli, D; Menzo, S; Mikagi, A; Mironov, VS; Misawa-Suzuki, T; Miwata, S; Mizuta, Y; Mohanan, PV; Mondal, J; Morici, P; Morita, K; Morozzo Della Rocca, B; Morris, T; Morsali, A; Morzhukhina, MV; Motta, S; Muramatsu, H; Naidu, R; Narita, A; Narita, K; Nasralla, D; Nemcokova, M; Netukova, M; Nishikawa, E; Nishio, N; Niu, X; Niu, Y; Njølstad, P; Notarstefano, V; Nugroho, MA; Nørgård, BM; Okuno, Y; Olokede, O; Ong, SP; Osailan, A; Ouyang, Z; Ozyazicioglu, AF; Pan, F; Parui, A; Paul, R; Pavoni, E; Payne, TE; Peng, X; Pérez-Padilla, R; Perta, N; Peter, SC; Pierantoni, L; Pietrowska, M; Pissanou, T; Pollok, JM; Prasetio, A; Putra, FS; Qiang, C; Qiao, L; Qutob, HMH; Raptis, DA; Razzo, BM; Reichborn-Kjennerud, T; Reichert, TE; Remigio-Luna, A; Rexha, J; Rivani, E; Rizzato, C; Romagnoli, A; Rossolini, GM; Sa, LY; Saad, RA; Sakaguchi, H; Salesi, M; Salsabilla, Z; Sanderson, E; Sanderson, P; Savitha, DP; Schulz, D; Seker, IB; Selvaganapathy, PR; Sha, D; Shah, SF; Shaikhomar, OA; Sharma, D; Shi, C; Shi, P; Shrotri, A; Sidiq, DH; Simonov, SV; Singh, AK; Song, C; Song, T; Spanier, G; Spoerl, S; Staropoli, A; Statsenko, ME; Steinhauer, S; Stosic, A; Studeny, P; Sugaya, T; Sun, S; Sun, X; Sunbul, SA; Supandi, AR; Suzuki, K; Suzuki, Y; Szczepański, MJ; Takahashi, Y; Taniguchi, R; Tao, Y; Tesli, M; Thirión-Romero, I; Tong, D; Trucchi, E; Tsuchido, Y; Turchetti, C; Turkina, SV; Turner, AW; Uldbjerg, N; Vinale, F; Wakamatsu, M; Walton, MA; Wang, C; Wang, Q; Wang, W; Wang, Y; Wang, Z; Wehberg, S; Wei, ZL; Wen, B; Whiteside, TL; Whittingham, MS; Widodo, ADW; Widłak, P; Wright, AI; Wu, H; Wu, Y; Wu, YL; Xiang, LG; Xiao, G; Xie, B; Xie, L; Xin, H; Xiong, J; Xiong, X; Xu, C; Xu, S; Yagubskii, EB; Yakushev, IA; Yang, H; Yang, J; Yao, J; Yao, ZX; Ye, J; Yerneni, SS; Yirgu, A; Yoshida, N; Yoshida, T; Young, SD; Yu, DN; Yuksel, A; Zac, J; Zac, S; Zarifkar, AH; Zhai, Y; Zhang, F; Zhang, H; Zhang, JW; Zhang, L; Zhang, Q; Zhang, X; Zhang, Y; Zhao, D; Zhao, J; Zhao, M; Zheng, D; Zheng, J; Zhou, G; Zhou, H; Zhu, P; Zhu, T; Zhu, Y; Zimmerman, MA; Zou, X | 1 |
| Aklilu, A; Biru, M; Manilal, A; Mitiku, A; Tsalla, T; Woldemariam, M | 1 |
| Almasri, DM; Barnawi, MH; Bulbol, S; Thabit, AK | 1 |
| Chen, L; He, XP; Hong, SJ; Hua, J; Jing, RC; Luo, XY; Xue, HW; Yuan, CY; Yue, Y | 1 |
| König, E; Zollner-Schwetz, I | 1 |
| Gao, F; Lei, T; Liang, B; Su, J; Tan, Y; Zeng, H | 1 |
| Hasegawa, T; Maeda, M; Noma, H; Ota, E | 1 |
| Chacko, S; Maheshwari, TK; Murdeshwar, S; Sheikh, RY | 1 |
| Bai, Y; Chen, R; Hao, Y; Lu, X; Si, Z; Song, Z; Wan, Z; Wang, G; Wang, Q; Wang, Y; Zhang, M | 1 |
| Anderson, AJ; Burton, T; Dillon, R; Puzniak, L; Seare, J | 1 |
| Ciszek, M; Hryniewiecka, E; Jasińska, K; Pączek, L; Wilkowski, P | 1 |
| Bhavnani, SM; Ganesan, H; Gupta, VK; Melnick, D; Rubino, CM; Safir, MC; Talley, AK | 1 |
| Cao, SS; Cui, B; Cui, F; Cui, J; Fan, BY; Fan, TT; Guan, Y; Ji, B; Li, MY; Li, SR; Wang, JW; Wang, L; Yan, CY; Zhang, W | 1 |
| Chen, WC; Cheng, HY; Hung, CC; Lin, MH; Lin, YC; Shen, YC; Teng, CK | 1 |
| Abbey, L; Abdelghany, TM; Abdellatif, MH; Abdelmohsen, UR; Abduljaleel Alzawar, NS; Abid, MF; Abu Kasim, AFB; Abu Saad, H; Adolpho, LF; Agostini, F; Agrizii, AP; Ahmed, S; Akce, M; Åkesson, D; Al-Awaadh, AM; Al-Mutar, DMK; Al-Odayni, AB; Al-Rajhi, AMH; Alaaeldin, R; Alam, M; Alam, MM; Alanazi, MA; Alattar, H; Alawlaqi, MM; Aldebis, HK; Algehainy, NA; Almeida, AA; Aloisi, F; Alrahlah, A; Alsenani, F; Alshabib, A; Altemani, FH; Althagafi, A; Amari, A; Andronesi, AG; Antonyuk, M; Arantes, TD; Araújo, R; Arrotti, S; Asakura, T; Asib, N; Atlaskin, AA; Aung, MS; Axiaq, A; Azekawa, S; Bacon, S; Bagalagel, A; Balbinot, GS; Barnet, LS; Baroyi, SAHM; Barreto, F; Barth, Y; Barysheva, AV; Bassa, E; Basu, R; Basu, S; Bates, C; Bautista, LS; Beitl, K; Beloti, MM; Benatti, G; Benavent-Celma, C; Bentaher, A; Bergsland, N; Bernardino, AF; Bernhardt, A; Bhandari, RK; Bhaskaran, K; Bhate, K; Bhattacharjee, A; Bian, X; Bien, EM; Birch, M; Bishara, K; Biswas, JP; Bleha, R; Bocale, R; Bona, S; Boriani, G; Bouyssi, A; Bradley, D; Bravo-Sánchez, MG; Bressan, GC; Brik, A; Brizuela, A; Brockbank, KGM; Buchner, F; Bunc, M; Buscombe, JR; Butler, AJ; Buzaleh, AM; Buzin, MI; Cabrera-Capetillo, CA; Calvo, AM; Camerota, A; Campagna, G; Campisi, M; Cano, K; Cao, HST; Cardellini, S; Carvalho, AP; Carvalho, BCR; Castillo-Baltazar, OS; Cataldo, P; Chai, P; Chakraborty, S; Chalo, DM; Chan, MY; Chander, S; Changbunjong, T; Chappuis, CJF; Chee, RCH; Chen, C; Chen, CJ; Chen, E; Chen, M; Chen, X; Chen, Y; Cheng, HT; Cheng, MC; Cheow, HK; Chi, Y; Chirikova, NK; Chiu, SH; Cho, G; Cho, HR; Cho, S; Cho, SJ; Choe, A; Choe, YH; Chun, BS; Chun, Z; Cinque, A; Ciopec, M; Cladas, Y; Cleary, SP; Clermont, O; Cléroux, M; Cockburn, J; Collares, FM; Colombini-Ishikiriama, BL; Conn, BN; Cortina, JL; Cox, DRA; Crini, G; Croker, R; Cursaru, DL; Curtis, HJ; da Silva, KJG; Dalla Costa, T; Davy, S; de Araújo, BV; de Cassia Ribeiro Gonçalves, R; de Gaetano, F; de Gregorio, C; de Oliveira, MG; De Vera, MAT; de Vos, M; de-la-Fuente, I; Dell'Oca, I; Delles, M; Déméautis, T; Dempster, M; Deng, YH; Denisenko, Y; Descombes, C; Desideri, G; Devarbhavi, H; Devouassoux, G; Di Bella, G; Di Marco, F; Diao, Y; Dias, BB; Dilgin, Y; Dimopoulou, I; Dionísio, TJ; Dobrovic, A; Dokin, ES; Dolby, T; Dong, X; Dong, Y; Dou, SX; Douglas, IJ; Dousset, S; Du, Z; Duan, M; Duan, SB; Duke-Williams, O; Duteanu, N; Dutertre, S; Dutta, S; Dwyer, MG; Ebenbauer, J; Eggo, RM; El-Mordy, FMA; Elbhnsawi, NA; Elrehany, MA; Elshewemi, SS; Elwakil, BH; Emadzadeh, D; Eraso, E; Ermolenko, E; Erten, K; Ettorre, E; Evans, D; Evans, SJ; Faheem, M; Fallanza, M; Faramarzi, M; Faria, FAC; Faro, DC; Fatma, YS; Fazil, S; Feng, Y; Ferguson, J; Fernandes, MH; Fernández-Domínguez, M; Ferrari, LAL; Ferraz, EP; Ferreira, LC; Ferri, C; Fikry, M; Floris, M; Forbes, H; Fotouh, B; Franke, K; Freitas, AC; Freitas, GP; Frieboes, HB; Fu, B; Fu, Y; Fukina, DG; Fukuda, DH; Fukunaga, K; Fulham, GJ; Furlan, L; Furtado Mesa, M; Furtunescu, FL; Gabbieri, D; Ganash, M; Gebers, JC; Gehman, V; Ghaedi, A; Ghazali, NSM; Ghebrekristos, Y; Gil, J; Gilbert, NM; Gimenes, R; Giordano, L; Glehen, O; Godeau, C; Goh, SK; Goldacre, B; Gomes, AM; Gomes, MPO; Gomes, PS; Gomes, RMODS; Gómez-Coma, L; Grenho, L; Gu, Q; Gu, T; Gu, YC; Guiducci, V; Guillemin, JP; Guo, W; Guo, YW; Gur, E; Guridi, A; Guzmán-López, A; Gvozdenko, T; H Elmaidomy, A; Hagar, M; Haider, S; Han, JM; Hanratty, J; Hans, R; Haque, N; Harharah, HN; Harharah, RH; Harper, S; Hasegawa, N; Hassanin, AH; Hastuti, YP; Hatem, AE; He, R; He, Y; Heinemann, C; Heinmaa, I; Heinzl, F; Helfer, VE; Hester, F; Hickman, G; Hill, MA; Hill, WG; Hintze, V; Ho, JSY; Ho, LY; Hoang, T; Holzer, I; Houbraken, J; Hsu, CN; Hu, J; Hu, X; Hu, Y; Hua, T; Huang, Z; Hulme, WJ; Hunter, A; Ianăşi, C; Ibañez, R; Iezzi, R; Iliuță, L; Im, YM; Imran, M; Inglesby, P; Inguimbert, N; Iqbal, A; Izawa, N; Jahaj, E; Jain, S; Jakimovski, D; Jalal, MM; Jaroszuk-Ściseł, J; Jasim, DJ; Jauregizar, N; Javle, MM; Jędryczka, M; Ji, H; Jiang, Y; Jin, J; Johnson, NT; Joshi, S; Jullok, N; Kachapulula, PW; Kaczmarek, J; Kaczmarek-Szczepańska, B; Kadota, K; Kaji, M; Kakeji, Y; Kakizoe, S; Kakudidi, E; Kalitukha, L; Kamata, H; Kang, YJ; Kapinos, AA; Karakaya, S; Kashchenko, NI; Kasyanov, S; Kataky, R; Katati, B; Kato, G; Katsina, AU; Kaya, A; Kaya, H; Kazarina, OV; Ke, Y; Keenan, C; Keilson, JM; Keshavan, A; Keskinidou, C; Khalifa, MA; Khan, R; Khan, S; Kim, D; Kim, K; Kim, MS; Kim, SM; Kim, WH; Kim, Y; Kim, YJ; Kishimura, H; Kitagawa, RR; Klemenkova, ZS; Kloss, F; Kobayashi, N; Kohlhoff, M; Kong, WKF; Konsek, H; Kornaros, M; Kotanidou, A; Kovacs, S; Kraska, J; Kruppke, B; Kumagai, Y; Kumar, S; Kumari, R; Kuruva, V; Kuster, RM; Kusumoto, T; Kutyła, M; Kwon, JH; Kwon, SH; Kwong, KY; Kyser, AJ; Lackner, M; Lass-Flörl, C; Lauri, C; Lavandera, JV; Lee, BH; Lee, ECY; Lee, HJ; Lee, J; Lee, PS; Lee, S; Lee, SE; Lee, SY; Lefort, F; Leite, JPV; Leo, G; Leonard, R; Leow, AST; Lepori, N; Leyden, K; Leys, L; Ležaić, L; Li, D; Li, H; Li, J; Li, S; Li, TYW; Li, X; Li, XH; Li, Y; Li, Z; Li, ZH; Liao, S; Liaqat, K; Lim, H; Lin, BS; Lin, MY; Lin, NH; Lin, X; Lin, Y; Liu, C; Liu, H; Liu, HK; Liu, HX; Liu, P; Liu, R; Liu, T; Liu, X; Liu, Y; Lock, GA; Lokaj, G; Lopes, HB; Losi, V; Lotsios, NS; Low, KE; Lu, Z; Luhana, S; Luo, X; Luo, XQ; Lutz, MB; Lysova, AA; Lyssenko, KA; Macit, M; MacIver, B; MacKenna, B; Magalhães, GAP; Magnavacchi, P; Mahadevan, J; Mahboubi, A; Maher, SA; Mahipal, A; Mahmoud, MY; Maithel, SK; Makhtar, MMZ; Makurat-Kasprolewicz, B; Malysheva, YB; Mansourizadeh, A; Marek, EJ; Maresca-Fichter, H; Martin, JT; Maslov, AA; Mastora, Z; Mastroiacovo, D; Mastropetros, SG; Matei, D; Mathur, R; Matos, AO; Matsuda, Y; Maurya, SK; Mayor, Á; Mayrhofer, D; Mazzuco, AC; McCaffrey, J; McClure, T; McDonald, HI; Mchunu, NP; McLaggan, D; Mehrkar, A; Meilik, B; Melito, VA; Mellem, J; Mengozzi, A; Menotti, J; Mesquita, V; Miao, Z; Mihai, S; Miller, S; Minassian, C; Mirabile, A; Mitra, S; Mladin, G; Mo, Z; Moawad, H; Mohamed, EM; Mohammed, TJ; Mohanlall, V; Mohyeldin, RH; Moldovan, H; Monneret, G; Monopoli, DE; Monte, IP; Monteiro, JRB; Morgante, V; Mori, M; Morin-Crini, N; Morita, A; Morton, CE; Mrak, M; Muhammed, AP; Mulick, A; Muralidharan, V; Murthy, P; Muselli, M; Mustafa, S; Mysore Visweswariah, A; Nagao, G; Naicker, S; Nakagawara, K; Namgoong, B; Namkoong, H; Namukobe, J; Nasir, AA; Nasreen, SA; Natarajan, P; Nchiozem-Ngnitedem, VA; Necozione, S; Negrea, A; Negrea, P; Ngubane, S; Nguyen, TT; Nicke, A; Nightingale, E; Nistor, CL; Nitsch, D; Njapau, H; Noman, M; Novgorodtseva, T; Nowak, A; O'Connor, SR; Ofoe, R; Oh, K; Oh, TH; Oki, E; Olama, ZA; Olennikov, DN; Oliveira, GM; Omar, D; Ong, SJ; Orfanos, SE; Origa-Oryem, H; Orita, H; Ortiz, I; Ota, M; Ott, J; Otvagina, KV; Pacheco, N; Pacheco, RR; Padmanabhan, D; Pagan, JD; Pagnotta, PA; Palangi, V; Palanisamy, G; Palanisamy, K; Palanisamy, S; Pan, SG; Panaitescu, E; Pang, X; Panoutsakopoulos, V; Parera, VE; Park, JI; Park, JS; Park, SW; Park, Y; Park, YS; Parkash, O; Parry, J; Parry, JP; Paul, SK; Pavšič, N; Pałubicka, A; Persat, F; Petriz-Prieto, MA; Petukhov, AN; Pham, T; Pillay, S; Poh, KK; Ponomarev, II; Pontons-Melo, JC; Posa, A; Powell, E; Priya, AK; Punekar, R; Puppin Rontani, RM; Purushottam, M; Pusphanathan, K; Qi, JY; Qin, J; Qin, Z; Qiu, B; Qiu, X; Quattrini, G; Quindós, G; Qureshi, F; Rabbany, MA; Rac-Albu, M; Rac-Albu, ME; Rădulescu, BC; Rafatullah, M; Rajab, TK; Rajna, S; Ramanathan, M; Rao, D; Raviglione, D; Razorenov, DY; Redd, MJ; Rehman, W; Reig, M; Rentsch, CT; Ribeiro, LMS; Robles, D; Rocchi, S; Rocha, FG; Rodrigues, C; Rodrigues, LA; Rodrigues, RP; Roh, GH; Ronowska, A; Root, A; Rosa, AL; Rossi, R; Roy, S; Roy, VC; Rupji, M; Saber, EA; Sadarat, F; Saed, Y; Saeed, WS; Saeki, H; Saha, B; Saiwichai, T; Sakowicz-Burkiewicz, M; Sampedro, T; Sands, K; Santos, CF; Sari, M; Sathi, FA; Sauro, S; Sazanova, TS; Scafa-Udriște, A; Schoustra, SE; Schultze, A; Seo, DJ; Sevillano, E; Sezmis, G; Sgura, FA; Shah, NNAK; Shani, N; Shankarappa, B; Sharkey, LM; Sharma, VK; Sharp, C; Shehata, N; Shelton, N; Shieh, PB; Shimokawa, M; Shin, J; Shin, SH; Shin, YN; Shin, YR; Shipilova, A; Shoparwe, NF; Shukor, H; Sia, CH; Siddiqui, MH; Siddiqui, MR; Siena, V; Signore, A; Silwane, B; Siqueira-Sandrin, VS; Siregar, A; Sirignano, P; Sit, NW; Skidmore, S; Skupov, KM; Smeeth, L; Smoczer, C; Smolyanskiy, E; Sohn, H; Solodeev, I; Solovyev, A; Şomoghi, R; Song, F; Song, H; Song, Z; Souf, YM; Sousa, SC; Souza, MT; Steinbach-Rankins, JM; Stockton, J; Stout, JR; Su, K; Su, MZ; Suarez-Lopez, YA; Sukkurd, R; Sultanov, R; Sun, Y; Sun, Z; Supernak, M; Supriyono, E; Suroshe, SS; Suvorov, SS; Svera M Ianăşi, P; Switchenko, JM; Syarif, NY; Synytsya, A; Taherzadeh, MJ; Tain, YL; Tamburino, C; Tammam, OY; Tan, BYQ; Tan, H; Tan, S; Tanaka, H; Tang, R; Tang, X; Tang, Z; Taurino, M; Tazare, J; Teresi, L; Testro, A; Thanasoponkul, W; Thangarasu, S; Thavaselvam, D; Theodoro, RC; Theron, G; Thomas, RH; Thomson, JJ; Tian, X; Tian, Y; Tomaszewski, CA; Tomlinson, LA; Torres, CMME; Tóth, M; Trecourt, A; Trevisani, F; Trimarchi, G; Tristán, C; Truong, VK; Tsigkou, K; Tsutsumi, S; Ubukata, Y; Uehara, H; Uwamino, Y; Vahedi-Shahandashti, R; Valberg, SJ; Valderrama, C; Valdovinos-García, EM; Valsecchi, D; van Diepeningen, AD; van West, P; Vargas-Osuna, E; Vassall, M; Vassilaki, N; Vassiliou, AG; Vecino, X; Velez-Irizarry, D; Venkatesh, YN; Vignali, L; Virdis, A; Viswanath, B; Voisin, AS; Volkova, YA; Vorotyntsev, AV; Vorotyntsev, IV; Vtyurina, ES; Vu, DH; Waldridge, B; Walker, AJ; Wallon, M; Wang, B; Wang, G; Wang, H; Wang, J; Wang, LJ; Wang, S; Wang, T; Wang, X; Wang, Z; Warren, RM; Warren-Gash, C; Wei, SH; Weinstock-Guttman, B; Wekwejt, M; Wessjohann, LA; Wiesmann, HP; Williams, ZJ; Williamson, EJ; Wilson, M; Wing, K; Wong, AY; Wong, BKL; Woodward, S; Wozniak, KL; Wu, C; Wu, K; Wu, S; Wu, Y; Xiang, D; Xie, H; Xiong, X; Xu, C; Xu, H; Xu, J; Xu, WH; Xu, Y; Xun, T; Yamaguchi, S; Yan, P; Yan, W; Yan, Z; Yang, B; Yang, F; Yang, L; Yao, XB; Yasui, H; Yenesew, A; Yeo, LLL; Yeo, TC; Yi, S; Yin, F; Yip, JWL; Yoon, SH; Yoon, SJ; Yoshida, M; Yoshizumi, T; Young, LA; Yu, C; Yu, DD; Yu, F; Yu, H; Yu, JD; Yu, NJ; Yu, X; Yuan, Y; Yurenko, A; Yusof, YA; Zahedipoor, A; Zahran, EM; Zainuddin, NI; Zanatta, AC; Zanotto, ED; Zanozin, ID; Zavascki, AP; Zenke, M; Zhang, F; Zhang, G; Zhang, H; Zhang, J; Zhang, L; Zhang, MX; Zhang, NY; Zhang, Q; Zhang, W; Zhang, X; Zhang, XM; Zhao, F; Zhao, Q; Zhao, R; Zhao, Y; Zheng, J; Zheng, S; Zhou, L; Zhou, X; Zhu, H; Zivadinov, R; Žižek, D; Zuccoli, JR; Zwaan, BJ | 1 |
| Ghasemi, H; Sabouri, M; Seyedifar, M; Soodi, O | 1 |
| Jeon, K; Jeong, S; Lee, N; Park, MJ; Song, W | 1 |
| Abd-Al-Ridha Al-Abdullah, A; Ali Albadery, A; Shakir Mahdi Al-Amara, S | 1 |
| Fihman, V; Lafaurie, M; Lepeule, R; Lescure, X; Lesprit, P; Nguyen, Y; Oubaya, N; Senard, O; Therby, A | 1 |
| Higuita-Gutiérrez, LF; Jiménez-Quiceno, JN; Vargas-Alzate, CA | 1 |
| Chao, CM; Lai, CC; Tang, HJ | 1 |
| Essack, SY; Feldman, C; Maningi, NE; Mbelle, N; Modipane, L; Osei Sekyere, J | 1 |
| Link, I; Loose, M; Naber, KG; Wagenlehner, FME | 1 |
| Aznarte-Padial, P; Calleja-Hernández, MÁ; Expósito-Ruiz, M; Hidalgo-Tenorio, C; Jimenez-Morales, A; Sadyrbaeva-Dolgova, S | 1 |
| David, SSB; Maor, Y; Schwartz, O; Yossepowitch, O; Zohar, I | 1 |
| Girija, SA; Paramasivam, A; Priyadharsini, JV | 1 |
| Aliyev, B; Kalemci, S; Kizilay, F; Köse, T; Pullukçu, H; Şimşir, A; Taşbakan, M | 1 |
| Chen, L; Lan, Y; Li, X; Li, Y; Liang, X; Mo, C; Pan, Q; Tan, X | 1 |
| Ackley, R; Anderson, WE; Capraro, GA; Meredith, J; Minor, S; Polk, C; Roshdy, D | 1 |
| Benson, M; Braxton, JR; Clatworthy, AE; Cosimi, LA; Cummins, K; Earl, AM; Ernst, CM; Hung, DT; Li, L; Manson, AL; Nair, AV; Pironti, A; Rodriguez-Osorio, CA; Zagieboylo, AP | 1 |
| Almatroudi, A; Khurshid, M; Rasool, MH; Saqalein, M; Taj, Z | 1 |
| Cotroneo, N; Critchley, IA; Pillar, C; Pucci, MJ; Rubio, A | 1 |
| Barquist, L; Blaskovich, MAT; Boinett, CJ; Butler, MS; Cain, AK; Cooper, MA; Edwards, IA; Elliott, AG; Huang, JX; Lociuro, S; Lundberg, CV; Mobli, M; Neve, S; Porter, KM; Steen, J; Strandh, M; Zuegg, J | 1 |
| Álvarez, E; Barrera, E; Cardoso, B; Cerdeira, L; Cifuentes, S; Esposito, F; Gonzalez-Rocha, G; Lincopan, N; Moura, Q; Opazo-Capurro, A | 1 |
| Bonten, MJM; Damen, JAA; Ten Doesschate, T; van der Vaart, TW; van Werkhoven, CH | 1 |
| Deemer, K; Fronczek, C; Grey, J; Marr, K | 1 |
| Ariyasu, M; Bassetti, M; Doi, Y; Echols, R; Ferrer, R; Lodise, TP; Matsunaga, Y; Naas, T; Nagata, TD; Niki, Y; Paterson, DL; Portsmouth, S; Torre-Cisneros, J; Toyoizumi, K; Wunderink, RG | 1 |
| Cerrato, SG; Medeiros, EA; Salles, TCG; Santana, TF | 1 |
| Aguado, JM; Cano, Á; Carratalà, J; Clemente, WT; Cohen-Sinai, N; Cordero, E; Coussement, J; David, MD; Eriksson, BM; Fernández-Ruiz, M; Freire, MP; Grossi, PA; Gunseren, F; Gutiérrez-Gutiérrez, B; Hamiyet Demirkaya, M; Iyer, RN; Koçak Tufan, Z; Loeches, B; López-Medrano, F; Martín-Dávila, P; Martínez-Martínez, L; Mehta Steinke, S; Merino, E; Montejo, M; Mularoni, A; Oriol, I; Pascual, Á; Paul, M; Pérez-Nadales, E; Pierrotti, LC; Pilmis, B; Rana, M; Rizzi, M; Rodríguez-Baño, J; Roilides, E; San-Juan, R; Seminari, EM; Soldani, F; Tan, BH; Torre-Cisneros, J; Valerio, M; van Delden, C | 1 |
| Nathanson, BH; Shorr, AF; Sulham, K; Zilberberg, MD | 1 |
| Davido, B; Delory, T; Gaube, G; Gravier, S; Lafaurie, M; Le Pluart, D; Lepeule, R; Lesprit, P; Piet, E; Simeon, S | 1 |
| Cai, B; Kanakamedala, H; Shields, RK; Zhou, Y | 1 |
| Cai, Y; Liang, B; Wang, J; Zhang, H | 1 |
| Bronk, M; Gołębiewska, J; Krawczyk, B; Oggioni, MR; Wysocka, M; Zamudio, R | 1 |
| Bitsori, M; Galanakis, E; Maraki, S; Vergadi, E | 1 |
| Bonten, MJ; Bravo-Ferrer, J; Cuperus, N; Daikos, G; de Kraker, M; Feifel, J; Folgori, L; Goossens, H; Gutiérrez-Gutiérrez, B; Kostyanev, T; O'Brien, S; Pascual, A; Raka, L; Rodríguez-Baño, J; Sojo-Dorado, J | 1 |
| Chan, MC; Chang, FY; Chiu, SK; Huang, LY; Lin, JC; Lin, YT; Lu, PL; Siu, LK; Yeh, KM | 1 |
| Fan, W; Nathanson, BH; Shorr, AF; Sulham, K; Zilberberg, MD | 2 |
| Álvarez-Otero, J; Arca-Blanco, A; Bermúdez-Sanjurjo, JR; de la Fuente-Aguado, J; Fernández-Soneira, MJ; González-González, L; Lamas-Ferreiro, JL; Rodríguez-Conde, I | 1 |
| Abe, Y; Fukuchi, K; Hashimoto, K; Hibino, S; Inan-Erdogan, I; Itabashi, K; Matsuhashi, K; Ogawa, Y; Sakurai, S; Ugajin, K; Wakabayashi, H; Watanabe, Y | 1 |
| Akhi, MT; Ghotaslou, R; Kafil, HS; Khalili, Y; Naghili, B; Sheikhalizadeh, V; Yousefi, S | 1 |
| Bias, TE; Doyle, AM; Lee, DH; Malat, GE; Sharma, A | 1 |
| Bialek-Davenet, S; Brisse, S; Duprilot, M; Mayer, N; Nicolas-Chanoine, MH; Pagès, JM; Vergalli, J | 1 |
| Goto, K; Ito, K; Itoh, H; Kaneko, T; Kurogi, S; Nonoshita, K; Ohchi, Y; Sato, Y; Suzuki, Y; Tanaka, R; Ueno, T; Yasuda, N | 1 |
| Brown, J; Dumyati, G; Hoffmann, C; Holt, K; Khadem, T; Stevens, V | 1 |
| Altshuler, J; Fedorenko, M; Kim, SA; Paris, D | 1 |
| Grant, M; Holt, S; Thompson-Brazill, KA | 1 |
| Carbo, J; Conway, EL; Kurtzhalts, K; Lin, K; Mergenhagen, KA; Ott, MC; Sellick, JA | 1 |
| Abbo, LM; Bonomo, RA; Camargo, JF; Hujer, AM; Martinez, O; Perez, F; Perez-Cardona, A; Rojas, LJ; Rosa, R; Rudin, SD | 1 |
| Achard, MES; Anderson, GJ; Djoko, KY; Hancock, SJ; Harris, PN; Lo, AW; McEwan, AG; Miraula, M; Mitić, N; Paterson, DL; Peters, KM; Phan, MD; Prombhul, S; Schembri, MA; Schenk, G; Shafer, WM; Sidjabat, HE; Walsh, TR | 1 |
| Batra, J; Doda, A; Gandhoke, I; Grover, SS; Gupta, N; Hans, C; Khare, S | 1 |
| Huang, D; Jacobs, DM; Minhaj, F; Parker, A; Rao, GG; Safir, MC | 1 |
| Cai, J; Cao, B; Chen, H; Gu, B; Guo, Z; Hu, T; Huang, J; Huang, W; Jia, X; Jin, L; Li, B; Li, H; Li, W; Liao, K; Liu, L; Ma, X; Man, S; Pei, F; Tian, J; Wang, H; Wang, Q; Wang, S; Wen, H; Xie, L; Yang, C; Yang, H; Yin, Y; Zhang, L; Zhang, X; Zhang, Y; Zou, C | 1 |
| Cha, CJ; Jeon, JH; Jeong, BC; Kim, YB; Lee, CR; Lee, JH; Lee, SH; Park, KS | 1 |
| Béchet, S; Biscardi, S; Bonacorsi, S; Cixous, E; Cohen, R; Craiu, I; Dubos, F; Galerne, A; Grimprel, E; Hees, L; Hentgen, V; Jung, C; Levy, C; Lorrot, M; Madhi, F; Timsit, S | 1 |
| Britt, NS; Burnham, CA; Durkin, MJ; Hampton, NB; Kollef, MH; Micek, ST; Ritchie, DJ | 1 |
| Angoulvant, F; Bontemps, S; Cohen, R; Dessein, R; Dubos, F; Lagree, M; Madhi, F; Martinot, A | 1 |
| Bertrand, X; Bouiller, K; Bouxom, H; Fournier, D; Hocquet, D | 1 |
| Alonso-Isa, M; Benítez-Sala, R; Garcia-Gonzalez, L; Gil-Moradillo, J; Justo-Quintas, J; Lara-Isla, A; Medina-Polo, J; Sopeña-Sutil, R; Tejido-Sanchez, A | 1 |
| David-Neto, E; de Paula, FJ; Freire, MP; Mendes, CV; Nahas, WC; Pierrotti, LC; Piovesan, AC; Spadão, F | 1 |
| Cui, M; Gao, Y; Gu, ZC; Zhang, C; Zhang, ZL; Zhao, XY; Zhong, H | 1 |
| Jain, A; Pucci, MJ; Rubio, A | 1 |
| Beader, N; Bedenić, B; Bielen, L; Franolić, I; Lukić-Grlić, A; Meštrović, T; Mihaljević, S; Zarfel, G | 1 |
| Fujisawa, M; Hadi, U; Kinoshita, S; Kitagawa, K; Kuntaman, K; Mertaniasih, NM; Nishimoto, K; Osawa, K; Rahardjo, D; Sato, K; Shigemura, K; Shirakawa, T; Yamada, N; Yamamichi, F | 1 |
| Fujisawa, M; Fukuda, T; Kitagawa, K; Osawa, K; Sato, K; Shigemura, K; Shirakawa, T; Takasaka, A; Wakabayashi, S; Yamamichi, F | 1 |
| Gupta, V; McCann, E; Sung, AH; Tabak, YP; Vankeepuram, L; Ye, G | 1 |
| Naber, KG; Wagenlehner, FME | 1 |
| Alharbi, A; Alshehri, S; Eljaaly, K; Ortwine, JK; Pogue, JM | 1 |
| Benzerara, Y; Compain, F; Constant, AL; Gallah, S; Garnier, M; Guerot, E; Labbe, V; Mainardi, JL; Montil, M; Quesnel, C; Siami, S; Vimont, S | 1 |
| Gutiérrez-Gutiérrez, B; Rodríguez-Baño, J | 1 |
| Baillon-Plot, N; Charbonneau, C; Di Virgilio, R; Falcone, M; Kongnakorn, T; Tichy, E; Wagenlehner, F | 1 |
| Pati, J; Pattnaik, SK; Ray, B; Sahu, S; Sinha, S | 1 |
| Demir, M; Kazanasmaz, H | 1 |
| Campbell, J; Deas, CM; Kyle, JA; White, CW | 1 |
| Fujisawa, M; Kitano, H; Matsubara, A; Ohge, H; Shigemura, K; Teishima, J | 1 |
| Kaniga, K; Lee, M; Redman, R; Rice, DA | 1 |
| Baziaka, F; Galani, L; Giamarellou, H; Karaiskos, I | 1 |
| Hernández, E; Picazo, JJ; Rodríguez-Avial, C; Rodríguez-Avial, I | 1 |
| Antonelli Incalzi, R; Coppola, A; Laudisio, A; Marinosci, F; Rodano, L; Zizzo, A | 1 |
| Abreu-Lanfranco, O; Bheemreddy, S; Dhar, S; Hayakawa, K; Kaye, KS; Lephart, PR; Marchaim, D; Martin, ET; Mynatt, RP; Pogue, JM; Sunkara, B; Zhao, JJ | 1 |
| Kurtinecz, M; Li, G; Mitrani-Gold, FS; Mundy, LM; Singh, KP; Tomayko, JF; Wetherington, J | 1 |
| Falagas, ME; Lourida, P; Poulikakos, P; Rafailidis, PI; Tansarli, GS | 1 |
| Apisarnthanarak, A; Bhooanusas, N; Mundy, LM; Yaprasert, A | 1 |
| Couto, N; Endimiani, A; Perreten, V; Pomba, C; Rossano, A; Saial, D | 1 |
| Anh, ND; Chan, WM; Garcia, J; Harijanto, E; Lee, C; Loo, CM; Mustafa, M; Van Kinh, N | 1 |
| Clarke, LG; Doi, Y; Qureshi, ZA; Shields, RK; Syed, A | 1 |
| Lortholary, O; Parize, P; Pilmis, B; Zahar, JR | 1 |
| Bille, E; Emirian, A; Groh, M; Guet-Revillet, H; Join-Lambert, O; Jullien, V; Nebbad-Lechani, B; Weiss, E; Zahar, JR | 1 |
| Couzigou, C; Lambert, T; Le Monnier, A; Mizrahi, A; Nguyen Van, JC; Vidal, B | 1 |
| Brizendine, KD; Cober, ED; Richter, SS; van Duin, D | 1 |
| Li, J; Mukhopadhyay, A; Tambyah, PA; Vasudevan, A; Yuen, EG | 1 |
| Asakura, T; Ikeda, M; Kodera, S; Nakamura, A | 1 |
| Bonomo, RA; Cober, E; Evans, S; Fowler, VG; Kalayjian, RC; Kaye, KS; Perez, F; Richter, SS; Salata, RA; van Duin, D | 1 |
| Bonomo, RA; Ishii, Y; Mano, Y; Saga, T; Tateda, K; Yamaguchi, K; Yoshizumi, A | 1 |
| Eslami, G; Langaee, T; Rafati, M; Rafiei, A; Rezai, MS; Salehifar, E; Shafahi, K | 1 |
| Nieberg, P; Ny, P; Wong-Beringer, A | 1 |
| Barauskas, V; Bradley, JS; Cannavino, CR; Castaneda-Ruiz, B; Cirillo, I; Emeryk, A; Go, O; Redman, R; Senatorova, G | 1 |
| Bulanda, M; Chmielarczyk, A; Heczko, PB; Maciąg, J; Pobiega, M; Pomorska-Wesolowska, M; Romaniszyn, D; Wojkowska-Mach, J; Ziolkowski, G | 1 |
| Appannanavar, SB; Hallur, V; Mohan, B; Sandhu, HK; Singh, G; Taneja, N | 1 |
| Han, SB; Jeong, DC; Kang, JH; Lee, SC; Lee, SY | 1 |
| Cprek, JB; Gallagher, JC | 1 |
| Kamath, S; M Shenoy, S; Sinha, R | 1 |
| Bae, SH; Choi, JY; Han, NI; Jang, JW; Lee, JI; Lee, SW; Noh, YS; Ro, SM; Yoon, SK | 1 |
| Dong, F; Guo, L; Li, S; Liu, G; Liu, L | 1 |
| Gurevich, KG; Shulakova, OA; Zyryanov, SK | 1 |
| Armstrong, J; Carmeli, Y; Gasink, LB; Laud, PJ; Newell, P; Stone, G; Wardman, A | 1 |
| Bueno, MF; Cury, AP; David Neto, E; de Faro, LB; de Oliveira Garcia, D; de Paula, FJ; Di Gioia, TS; Francisco, GR; Freire, MP; Levin, AS; Nahas, WC; Pierrotti, LC; Piovesan, AC; Rossi, F; Spadão, F; Tomaz, M | 1 |
| Andreassen, S; Dickstein, Y; Geffen, Y; Leibovici, L; Paul, M | 1 |
| Fransén, J; Hanberger, H; Huss, FR; Nilsson, LE; Rydell, U; Sjöberg, F | 1 |
| Armstrong, J; Gasink, LB; Huang, X; Newell, P; Sobel, JD; Stone, GG; Wagenlehner, FM; Yates, K | 1 |
| Fukuchi, T; Iwata, K; Kobayashi, S; Nakamura, T; Ohji, G | 1 |
| Chavda, KD; Chen, L; Dever, LL; Kreiswirth, BN; Mathema, B; Mediavilla, JR; Patrawalla, A; Vinnard, C | 1 |
| Bel Haj Khalifa, A; Bouallègue, O; Boujâafar, N; Chaouch, C; Haenni, M; Madec, JY; Mansour, W; Messaoudi, A; Naija, W; Saras, E | 1 |
| Barchiesi, F; Castelli, P; Fiorentini, A; Manso, E; Mocchegiani, F; Montalti, R; Nicolini, D; Staffolani, S; Vivarelli, M | 1 |
| Camargo, CH; Costa, SF; de Maio Carrilho, CM; de Oliveira, LM; Gaudereto, J; Grion, CM; Levin, AS; Perozin, JS; Urbano, MR | 1 |
| Chao, CM; Chen, CC; Chuang, YC; Huang, HL; Lai, CC; Tang, HJ | 1 |
| Hackel, MA; Hoban, DJ; Karlowsky, JA; Lob, SH; Sahm, DF | 1 |
| Alonso-Isa, M; Benítez-Sala, R; García-Rojo, E; Gil-Moradillo, J; González-Padilla, DA; Justo-Quintas, J; Lara-Isla, A; Medina-Polo, J; Passas-Martínez, JB; Sopeña-Sutil, R; Tejido-Sánchez, Á | 1 |
| Janse van Rensburg, S; Lekalakala, MR; Mbelle, N; Tshisevhe, VS; Tshuma, N | 1 |
| Alp, E; Badal, R; Gulay, Z; Koksal, I; Korten, V; Lob, S; Mete, B; Mulazimoglu, L; Oguz, VA; Tabak, F; Unal, S; Yilmaz, G; Zarakolu, P | 1 |
| Fernando, MM; Gunathilake, MP; Luke, WA; Miththinda, JK; Premaratna, R; Sebastiampillai, BS; Silva, FH; Wickramasinghe, RD | 1 |
| Barmpouti, E; Galani, L; Giamarellou, H; Karaiskos, I; Masgala, A; Souli, M | 1 |
| Jitmuang, A; Kiratisin, P; Rattanaumpawan, P; Thamlikitkul, V; Werarak, P | 1 |
| Goff, DA; Mangino, JE; Schafer, JJ | 1 |
| Naber, KG; Redman, R; Wagenlehner, C; Wagenlehner, FM; Weidner, W | 1 |
| Lortholary, O; Martin, C; Nordmann, P; Plesiat, P; Potel, G; Zahar, JR | 1 |
| Depestel, DD; Paterson, DL | 1 |
| Hedrich, D; Kaniga, K; Kotey, P; Llorens, L; Naber, KG; Redman, R | 1 |
| Doi, K; Kobayashi, T; Matsumoto, T; Muratani, T; Nakamura, T | 1 |
| Guery, BP | 1 |
| Lin, R; Nandy, P; Samtani, MN | 1 |
| Markou, F; Pitiriga, V; Poulou, A; Pournaras, S; Ranellou, K; Spanakis, N; Tsakris, A | 1 |
| Ko, KS; Lee, H; Peck, KR; Song, JH | 1 |
| Khan, AU; Shakil, S | 1 |
| Arda, B; Pullukcu, H; Senol, S; Sipahi, H; Sipahi, OR; Tasbakan, M; Ulusoy, S; Yamazhan, T | 1 |
| Bonomo, RA | 1 |
| Binotto, E; George, N; Hayashi, Y; Htin, A; Li, J; Nation, RL; Nimmo, GR; Paterson, DL; Sidjabat, H; Walsh, TR | 1 |
| Alexander, DC; Lastovetska, O; Low, DE; Melano, RG; Patel, SN; Richardson, D; Tijet, N | 1 |
| Damiao, R; Davies, T; Kaniga, K; Kotey, P; Naber, KG; Redman, R | 1 |
| Atalay, H; Biyik, Z; Genc, N; Solak, Y; Turkmen, K; Yeksan, M | 1 |
| Aznar, E; García-Lozano, T; Gimeno, C; Lorente, P | 1 |
| Merino, P; Picazo, JJ; Rodríguez-Avial, C; Rodríguez-Avial, I | 1 |
| Blumenthal, JS; Calfee, DP; Cohen, AB; Furuya, EY; Jenkins, SG; Kubin, CJ; Satlin, MJ; Wilson, SJ | 1 |
| Lee, CK; Lee, K; Roh, KH; Sohn, JW; Song, W; Yong, D | 1 |
| Chau, F; Fantin, B; Le, P; Lefort, A; Lepeule, R; Massias, L; Nucci, A; Ruppé, E | 1 |
| Boulanger, AE; Nordmann, P; Poirel, L | 1 |
| Al Najjar, M; Hamzeh, AR; Mahfoud, M | 1 |
| Chiu, CH; Su, LH; Wu, TL | 1 |
| Aramă, V; Breuil, J; Hristea, A; Olaru, ID; Popoiu, M | 1 |
| Chen, YH; Chen, YS; Chuang, YC; Ho, CM; Hsueh, PR; Huang, CC; Ko, WC; Lee, YL; Liu, CE; Liu, YC; Liu, YM; Lu, PL; Ni, Y; Tang, HJ; Toh, HS; Wang, JH; Xu, Y; Yu, KW | 1 |
| Hall, GS; Neuner, EA; Sekeres, J; van Duin, D | 1 |
| Doi, A; Harada, S; Iwata, K; Kamiya, T; Shimada, T | 1 |
| Bachmann, A; Bonkat, G; Braissant, O; Frei, R; Gasser, TC; Müller, G; Rieken, M; Tschudin-Suter, S; Widmer, AF; Wyler, S | 1 |
| Amicosante, G; Colì, A; Docquier, JD; Lombardi, G; Luzzaro, F; Perilli, M; Riccio, ML; Rossolini, GM; Toniolo, A | 1 |
| Gudiol, F; Marín, M | 1 |
| Nakahama, C | 1 |
| Oishi, K | 1 |
| Horii, T; Maekawa, M; Morita, M; Muramatsu, H | 1 |
| Conejo, MC; García, I; Martínez-Martínez, L; Pascual, A; Picabea, L | 1 |
| Ariza, J; Dominguez, MA; Gudiol, F; Peña, C; Pujol, M; Verdaguer, R | 1 |
| Kohno, S | 1 |
| Matsumoto, T; Muratani, T | 1 |
| Brink, AJ; Feldman, C; Grolman, DC; Muckart, D; Pretorius, J; Richards, GA; Senekal, M; Sieling, W | 1 |
| Horii, T; Iinuma, Y; Muramatsu, H | 1 |
| Ahmad, RN; Butt, T; Saif, I; Usman, M | 1 |
| Eta, S; Kawahara, M | 1 |
| Paterson, DL | 1 |
| Fraser, VJ; Fridkin, SK; Kollef, MH; Merz, LR; Warren, DK | 1 |
| Aksungar, FB; Ozakkaş, F; Topkaya, AE; Tülbek, Y | 1 |
| Ip, M; Kei, HW; Lau, WC; Lee, N; Marasinghe, T; Wong, KY; You, JH | 1 |
| Miyagi, T; Nakashima, T; Shigehara, K; Shimamura, M | 1 |
| Iwai, N; Nakamura, H | 1 |
| Hayakawa, F; Itomi, K; Kato, T; Kuno, K; Miyajima, Y; Ogawa, A; Okumura, A; Takahashi, H | 1 |
| Ihara, T; Itoh, M; Kamiya, H; Kitamura, K; Nakano, T; Sakurai, M | 1 |
| Abe, T; Hagiwara, N; Hata, M; Iitsuka, T; Kobayashi, M; Kubota, K; Kudou, S; Nakayama, T; Negishi, S; Tajima, T | 1 |
| Kuwahata, K; Niinou, K; Sato, H; Sigeta, M; Suzuki, H | 1 |
| Fujii, R; Meguro, H; Terashima, I | 1 |
| Ishihara, T; Nakamura, H; Tezuka, T; Toyonaga, Y | 1 |
| Arakawa, S; Hirose, T; Kamidono, S; Kumamoto, Y; Kumazawa, J; Matsumoto, T; Nishimura, M | 1 |
| Cravarezza, P; Romanelli, G | 1 |
| Beuscart, C; Mouton, YJ | 1 |
| Baldassarre, R; Comunale, L; Poletti, G; Tallarigo, C | 1 |
| Kumazawa, J; Matsumoto, T; Nagayama, A | 1 |
| Bischoff, W; Castellani, P; Herceg, R; Landi, V; Sassella, D | 1 |
| Hostacká, A | 1 |
| Eltahawy, AT | 1 |
| Cardoso, O; Leitão, R; Peixe, L; Sousa, JC | 1 |
| Iwatsubo, E; Kawakami, Y; Manabe, N; Matsumoto, T; Takahashi, K | 1 |
| Goto, N; Hara, K; Inoue, M; Kumon, H; Shinagawa, T; Ubukata, K; Watanabe, A | 1 |
| Nagayama, A; Nomura, S | 1 |
| Hofstetter, A | 1 |
| Edwards, JR; Nairn, K; Williams, S | 1 |
28 review(s) available for carbapenems and Urinary Tract Infections
| Article | Year |
|---|---|
Cefiderocol: A new Antimicrobial for Complicated Urinary Tract Infection (CUTI) Caused by Carbapenem-resistant Enterobacteriaceae (CRE).
Topics: Adult; Anti-Bacterial Agents; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Cefiderocol; Cephalosporins; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Male; Siderophores; Urinary Tract Infections | 2022 |
A review of recent advances in the treatment of adults with complicated urinary tract infection.
Topics: Adult; Anti-Bacterial Agents; Bacteria; beta-Lactamase Inhibitors; Carbapenems; Drug Resistance, Multiple, Bacterial; Humans; Urinary Tract Infections | 2022 |
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter Infections; Adaptation, Psychological; Adolescent; Adsorption; Adult; Aged; Alcohol Drinking; Alzheimer Disease; Amikacin; Ammonia; Anaerobiosis; Animals; Anorexia; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Anxiety; Aptamers, Nucleotide; Asthenia; Attention Deficit Disorder with Hyperactivity; Bacterial Proteins; Beryllium; beta-Lactamases; Biofuels; Biomass; Biosensing Techniques; Bismuth; Blister; Body Mass Index; Body Surface Area; Boronic Acids; Brain; Breast Neoplasms; Butyrylcholinesterase; Cannabis; Carbapenems; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Carboxylic Acids; Carcinoma, Hepatocellular; Cardiovascular Diseases; Carnitine; Case-Control Studies; Catalysis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Child; China; Cholinesterase Inhibitors; Clarithromycin; Clostridioides; Clostridioides difficile; Clostridium Infections; Cohort Studies; Colistin; Colitis; Colon; Coloring Agents; Coronary Artery Bypass; Creatinine; Crystalloid Solutions; Cytokines; Depression; Dextran Sulfate; Dextrans; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Diarrhea; Dietary Supplements; Diphenhydramine; Disease Models, Animal; Disease Outbreaks; Double-Blind Method; Doxorubicin; Drosophila; Drug Tapering; Dysbiosis; Electrons; Escherichia coli; Extracellular Vesicles; Fatigue; Female; Fermentation; gamma-Cyclodextrins; Gastrointestinal Microbiome; Glucose; Graft Survival; Graft vs Host Disease; Head and Neck Neoplasms; Heart Arrest, Induced; Hematopoietic Stem Cell Transplantation; High-Intensity Interval Training; Hippocampus; Humans; Hydrogen-Ion Concentration; Hypertension; Incidence; Interferon-gamma; Italy; Kinetics; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Lactoferrin; Larva; Length of Stay; Lignin; Liver; Liver Neoplasms; Liver Transplantation; Living Donors; Low Back Pain; Lung; Lung Volume Measurements; Macrophages; Male; Melphalan; Men; Mendelian Randomization Analysis; Meropenem; Methane; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mitochondrial Proteins; Molecular Docking Simulation; Molecular Structure; Mothers; Motivation; Mycoplasma; Mycoplasma hominis; Mycoplasma Infections; NAD; Nanocomposites; Nanoparticles; Nanotubes, Carbon; Naproxen; Neovascularization, Pathologic; Neurons; Nitrates; Nucleolin; Opuntia; Paratyphoid Fever; Phenotype; Phosphatidylinositol 3-Kinases; Phytochemicals; Plant Extracts; Pregnancy; Prevalence; Prospective Studies; Proto-Oncogene Proteins c-akt; Pulmonary Disease, Chronic Obstructive; Rats; Rats, Wistar; Resveratrol; Retrospective Studies; Rifampin; Risk Factors; RNA, Messenger; Selenium; Sleep; Social Behavior; Soil; Soil Pollutants; Squamous Cell Carcinoma of Head and Neck; Staphylococcus aureus; Structure-Activity Relationship; Suicidal Ideation; Suicide; Superoxide Dismutase-1; Surveys and Questionnaires; Swimming; Syndrome; Tannins; Temperature; Transforming Growth Factor beta; Transplantation Conditioning; Treatment Outcome; Triple Negative Breast Neoplasms; Troponin T; Tumor Microenvironment; United Kingdom; Ureaplasma; Ureaplasma urealyticum; Urinary Tract Infections; Viscum; Waste Disposal Facilities; Wastewater; Water; Water Pollutants, Chemical; Wolfiporia; Young Adult | 2022 |
Treatment options for multidrug-resistant Gram-negatives in urinary tract infections.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Gram-Negative Bacterial Infections; Humans; Imipenem; Urinary Tract Infections | 2023 |
Antimicrobial resistance and molecular epidemiology of carbapenem-resistant Escherichia coli from urinary tract infections in Shandong, China.
Topics: Anti-Bacterial Agents; Carbapenems; Drug Resistance, Bacterial; Escherichia coli Infections; Humans; Molecular Epidemiology; Phylogeny; Urinary Tract Infections; Uropathogenic Escherichia coli | 2023 |
Comparative efficacy and safety of non-polymyxin antibiotics against nosocomial pneumonia, complicated intra-abdominal infection, or complicated urinary tract infection: A network meta-analysis of randomised clinical trials.
Topics: Anti-Bacterial Agents; Carbapenems; Cross Infection; Gram-Negative Bacterial Infections; Healthcare-Associated Pneumonia; Humans; Intraabdominal Infections; Network Meta-Analysis; Randomized Controlled Trials as Topic; Urinary Tract Infections | 2023 |
Topics: Acetogenins; Acute Disease; Acute Kidney Injury; Administration, Intravenous; Aged; Albumins; Alcoholism; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; alpha-Glucosidases; Anemia; Animals; Anthozoa; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bacterial; Antigens, Bacterial; Antihypertensive Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Ascites; Asthma; Bacteria; beta-Lactamases; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Binding Sites; Biological Availability; Biomass; Borderline Personality Disorder; Brain; Brucella abortus; Brucella melitensis; Brucellosis; Calcium; Carbapenems; Case-Control Studies; Caseins; Cattle; CD8-Positive T-Lymphocytes; Ceftaroline; Cell Line; Cell Line, Tumor; Cell Physiological Phenomena; Cell Proliferation; Cephalosporins; Chemotherapy, Adjuvant; China; Chitin; Chlorella; Chlorophyll; Chlorophyll A; Chlorophyta; Cholangiocarcinoma; Cisplatin; Conotoxins; Contrast Media; Conus Snail; Cross-Sectional Studies; Cytokines; Decapodiformes; Deoxycytidine; Diagnostic and Statistical Manual of Mental Disorders; Dietary Fiber; Diterpenes; DNA Methylation; Dogs; Double-Blind Method; Drug Design; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Screening Assays, Antitumor; Eicosapentaenoic Acid; Enzyme-Linked Immunosorbent Assay; Epidermis; Escherichia coli; Escherichia coli Infections; Extraintestinal Pathogenic Escherichia coli; Fatty Acids; Fatty Acids, Unsaturated; Fatty Acids, Volatile; Feasibility Studies; Feces; Female; Ferritins; Fluorodeoxyglucose F18; Gastrectomy; Gastrointestinal Microbiome; Gemcitabine; Glomerular Filtration Rate; Glucose; Glycerol; Granulocyte-Macrophage Colony-Stimulating Factor; HeLa Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Hypoxia-Inducible Factor-Proline Dioxygenases; Immunoassay; Immunoglobulin G; India; Infant, Newborn; Infertility; Inflammation; Intensive Care Units; Iron; Iron Deficiencies; Kidney; Lacticaseibacillus rhamnosus; Laurencia; Leukocytes; Lipids; Liver Cirrhosis; Long Interspersed Nucleotide Elements; Longitudinal Studies; Male; Mesenchymal Stem Cells; Methicillin-Resistant Staphylococcus aureus; Mice; Microalgae; Microbial Sensitivity Tests; Microscopy; Middle Aged; Minerals; Molecular Conformation; Molecular Docking Simulation; Molecular Structure; Mycobacterium tuberculosis; Myeloid Cells; Myeloid-Derived Suppressor Cells; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nephropidae; Nicotinic Antagonists; Nitrogen; Obesity; Oxaliplatin; Paclitaxel; Panax; Pancreatic Neoplasms; Pancreatitis; Personality; Personality Disorders; Personality Inventory; Photobioreactors; Plant Extracts; Plasmalogens; Plasmids; Polymorphism, Genetic; Polynesia; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prebiotics; Predictive Value of Tests; Prognosis; Prolyl-Hydroxylase Inhibitors; Rabbits; Radiopharmaceuticals; Rats; Rats, Wistar; Receptors, Nicotinic; Recombinant Proteins; Retrospective Studies; Rifampin; Risk Factors; RNA, Ribosomal, 16S; Salinity; Seaweed; Sensitivity and Specificity; Sepsis; Sesquiterpenes; Severity of Illness Index; Shock, Septic; Silicones; Single Photon Emission Computed Tomography Computed Tomography; Skin; Snails; Solubility; Solvents; Sputum; Staphylococcal Infections; Stomach Neoplasms; Stramenopiles; Structure-Activity Relationship; Technetium Tc 99m Exametazime; Technology; Terpenes; Tuberculosis; Tuberculosis, Multidrug-Resistant; Urinary Catheters; Urinary Tract Infections; Vascular Endothelial Growth Factor A; Virulence Factors; Water; Wound Healing | 2023 |
Carbapenems vs alternative antibiotics for the treatment of complicated urinary tract infection: A systematic review and network meta-analysis.
Topics: Anti-Bacterial Agents; Carbapenems; Humans; Network Meta-Analysis; Urinary Tract Infections | 2020 |
Carbapenem-alternative strategies for complicated urinary tract infections: A systematic review of randomized controlled trials.
Topics: Anti-Bacterial Agents; Carbapenems; Humans; Intraabdominal Infections; Randomized Controlled Trials as Topic; Urinary Tract Infections | 2020 |
Non-carbapenem β-lactam/β-lactamase inhibitors versus carbapenems for urinary tract infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: a systematic review.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacteremia; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftazidime; Drug Combinations; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Urinary Tract Infections | 2021 |
Triple combination antibiotic therapy for carbapenemase-producing Klebsiella pneumoniae: a systematic review.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactamases; Carbapenems; Colistin; Drug Combinations; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Minocycline; Pneumonia; Polymyxin B; Polymyxins; Tigecycline; Treatment Outcome; Urinary Tract Infections | 2017 |
Antimicrobial Resistance of Hypervirulent
Topics: Bacteremia; Bacterial Capsules; Bacterial Proteins; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Humans; Hydroxamic Acids; Klebsiella Infections; Klebsiella pneumoniae; Liver Abscess; Molecular Epidemiology; Phylogeography; Serogroup; Urinary Tract Infections; Virulence; Virulence Factors | 2017 |
Evaluation of the efficacy and safety of ceftazidime/avibactam in the treatment of Gram-negative bacterial infections: a systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Ceftazidime; Colistin; Drug Administration Schedule; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Patient Safety; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Urinary Tract Infections | 2018 |
Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Clinical Trials as Topic; Colistin; Dose-Response Relationship, Drug; Drug Approval; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Meropenem; Randomized Controlled Trials as Topic; Sisomicin; United States; United States Food and Drug Administration; Urinary Tract Infections | 2019 |
Current options for the treatment of infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in different groups of patients.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Immunocompromised Host; Randomized Controlled Trials as Topic; Urinary Tract Infections | 2019 |
Current status of countermeasures for infectious diseases and resistant microbes in the field of urology.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Proteins; beta-Lactamases; Carbapenems; Catheter-Related Infections; Cell Wall; Centers for Disease Control and Prevention, U.S.; Cross Infection; Drug Resistance, Bacterial; Drug Therapy, Combination; Gonorrhea; Humans; Microbial Sensitivity Tests; Practice Guidelines as Topic; United States; Urinary Tract Infections; Urology; World Health Organization | 2019 |
Systematic review and meta-analysis of antimicrobial treatment effect estimation in complicated urinary tract infection.
Topics: Anti-Bacterial Agents; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Clinical Trials as Topic; Databases, Bibliographic; Doripenem; Drug Combinations; Female; Humans; Imipenem; Levofloxacin; Male; Research Design; Treatment Outcome; Urinary Tract Infections | 2013 |
Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence.
Topics: Anti-Bacterial Agents; Bacteremia; beta-Lactam Resistance; Carbapenems; Colistin; Critical Illness; Drug Therapy, Combination; Enterobacteriaceae; Humans; Minocycline; Pneumonia, Bacterial; Survival Analysis; Tigecycline; Urinary Tract Infections | 2014 |
Doripenem: a new addition to the carbapenem class of antimicrobials.
Topics: Anti-Bacterial Agents; Carbapenems; Cross Infection; Doripenem; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Pneumonia, Ventilator-Associated; Urinary Tract Infections | 2009 |
Addressing the challenge of extended-spectrum beta-lactamases.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Community-Acquired Infections; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Humans; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome; Urinary Tract Infections | 2009 |
Doripenem.
Topics: Carbapenems; Doripenem; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Peritonitis; Pneumonia, Bacterial; Seizures; Urinary Tract Infections | 2009 |
[Doripenem: need for a new carbapenem].
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Burkholderia cepacia; Carbapenems; Clinical Trials as Topic; Cross Infection; Doripenem; Drug Evaluation, Preclinical; Drug Resistance, Multiple, Bacterial; Humans; Nervous System Diseases; Peritonitis; Pneumonia, Bacterial; Pseudomonas aeruginosa; Urinary Tract Infections | 2009 |
[Klebsiella infection].
Topics: 4-Quinolones; Anti-Infective Agents; beta-Lactamases; Carbapenems; Cephalosporins; Drug Resistance, Bacterial; Humans; Klebsiella Infections; Klebsiella pneumoniae; Penicillinase; Respiratory Tract Infections; Sepsis; Urinary Tract Infections | 2003 |
[Pseudomonas aeruginosa infection].
Topics: 4-Quinolones; Anti-Infective Agents; Bacteremia; Biofilms; Carbapenems; Cephalosporins; Fimbriae, Bacterial; Flagella; Humans; Immunocompromised Host; Multidrug Resistance-Associated Proteins; Prognosis; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Sepsis; Trans-Activators; Urinary Tract Infections | 2003 |
Newer carbapenems for urinary tract infections.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Carbapenems; Double-Blind Method; Enterobacteriaceae; Gram-Positive Cocci; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Randomized Controlled Trials as Topic; Urinary Tract Infections; Urine | 2004 |
Appropriate use of the carbapenems.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Carbapenems; Cilastatin; Community-Acquired Infections; Cross Infection; Drug Resistance, Bacterial; Drug Utilization; Ertapenem; Humans; Imipenem; Lactams; Meropenem; Patient Selection; Pneumonia, Bacterial; Practice Patterns, Physicians'; Protease Inhibitors; South Africa; Surgical Wound Infection; Thienamycins; Urinary Tract Infections | 2004 |
Resistance in gram-negative bacteria: enterobacteriaceae.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Carbapenems; Cephalosporins; Ciprofloxacin; Community-Acquired Infections; Drug Resistance, Bacterial; Drug Resistance, Multiple; Enterobacteriaceae; Enterobacteriaceae Infections; Gram-Negative Bacterial Infections; Humans; Klebsiella Infections; Quinolones; Urinary Tract Infections | 2006 |
[Multicenter comparative study of meropenem vs. imipenem in the intramuscular treatment of hospital infections of the urinary tract].
Topics: Adult; Aged; Carbapenems; Chi-Square Distribution; Cilastatin; Cross Infection; Female; Humans; Imipenem; Male; Meropenem; Middle Aged; Protease Inhibitors; Thienamycins; Urinary Tract Infections | 1995 |
27 trial(s) available for carbapenems and Urinary Tract Infections
| Article | Year |
|---|---|
Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection.
Topics: Administration, Intravenous; Administration, Oral; Adult; Anti-Bacterial Agents; Carbapenems; Double-Blind Method; Drug Resistance, Multiple, Bacterial; Ertapenem; Humans; Pyelonephritis; Urinary Tract Infections | 2022 |
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter Infections; Adaptation, Psychological; Adolescent; Adsorption; Adult; Aged; Alcohol Drinking; Alzheimer Disease; Amikacin; Ammonia; Anaerobiosis; Animals; Anorexia; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Anxiety; Aptamers, Nucleotide; Asthenia; Attention Deficit Disorder with Hyperactivity; Bacterial Proteins; Beryllium; beta-Lactamases; Biofuels; Biomass; Biosensing Techniques; Bismuth; Blister; Body Mass Index; Body Surface Area; Boronic Acids; Brain; Breast Neoplasms; Butyrylcholinesterase; Cannabis; Carbapenems; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Carboxylic Acids; Carcinoma, Hepatocellular; Cardiovascular Diseases; Carnitine; Case-Control Studies; Catalysis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Child; China; Cholinesterase Inhibitors; Clarithromycin; Clostridioides; Clostridioides difficile; Clostridium Infections; Cohort Studies; Colistin; Colitis; Colon; Coloring Agents; Coronary Artery Bypass; Creatinine; Crystalloid Solutions; Cytokines; Depression; Dextran Sulfate; Dextrans; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Diarrhea; Dietary Supplements; Diphenhydramine; Disease Models, Animal; Disease Outbreaks; Double-Blind Method; Doxorubicin; Drosophila; Drug Tapering; Dysbiosis; Electrons; Escherichia coli; Extracellular Vesicles; Fatigue; Female; Fermentation; gamma-Cyclodextrins; Gastrointestinal Microbiome; Glucose; Graft Survival; Graft vs Host Disease; Head and Neck Neoplasms; Heart Arrest, Induced; Hematopoietic Stem Cell Transplantation; High-Intensity Interval Training; Hippocampus; Humans; Hydrogen-Ion Concentration; Hypertension; Incidence; Interferon-gamma; Italy; Kinetics; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Lactoferrin; Larva; Length of Stay; Lignin; Liver; Liver Neoplasms; Liver Transplantation; Living Donors; Low Back Pain; Lung; Lung Volume Measurements; Macrophages; Male; Melphalan; Men; Mendelian Randomization Analysis; Meropenem; Methane; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mitochondrial Proteins; Molecular Docking Simulation; Molecular Structure; Mothers; Motivation; Mycoplasma; Mycoplasma hominis; Mycoplasma Infections; NAD; Nanocomposites; Nanoparticles; Nanotubes, Carbon; Naproxen; Neovascularization, Pathologic; Neurons; Nitrates; Nucleolin; Opuntia; Paratyphoid Fever; Phenotype; Phosphatidylinositol 3-Kinases; Phytochemicals; Plant Extracts; Pregnancy; Prevalence; Prospective Studies; Proto-Oncogene Proteins c-akt; Pulmonary Disease, Chronic Obstructive; Rats; Rats, Wistar; Resveratrol; Retrospective Studies; Rifampin; Risk Factors; RNA, Messenger; Selenium; Sleep; Social Behavior; Soil; Soil Pollutants; Squamous Cell Carcinoma of Head and Neck; Staphylococcus aureus; Structure-Activity Relationship; Suicidal Ideation; Suicide; Superoxide Dismutase-1; Surveys and Questionnaires; Swimming; Syndrome; Tannins; Temperature; Transforming Growth Factor beta; Transplantation Conditioning; Treatment Outcome; Triple Negative Breast Neoplasms; Troponin T; Tumor Microenvironment; United Kingdom; Ureaplasma; Ureaplasma urealyticum; Urinary Tract Infections; Viscum; Waste Disposal Facilities; Wastewater; Water; Water Pollutants, Chemical; Wolfiporia; Young Adult | 2022 |
Topics: Acetogenins; Acute Disease; Acute Kidney Injury; Administration, Intravenous; Aged; Albumins; Alcoholism; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; alpha-Glucosidases; Anemia; Animals; Anthozoa; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bacterial; Antigens, Bacterial; Antihypertensive Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Ascites; Asthma; Bacteria; beta-Lactamases; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Binding Sites; Biological Availability; Biomass; Borderline Personality Disorder; Brain; Brucella abortus; Brucella melitensis; Brucellosis; Calcium; Carbapenems; Case-Control Studies; Caseins; Cattle; CD8-Positive T-Lymphocytes; Ceftaroline; Cell Line; Cell Line, Tumor; Cell Physiological Phenomena; Cell Proliferation; Cephalosporins; Chemotherapy, Adjuvant; China; Chitin; Chlorella; Chlorophyll; Chlorophyll A; Chlorophyta; Cholangiocarcinoma; Cisplatin; Conotoxins; Contrast Media; Conus Snail; Cross-Sectional Studies; Cytokines; Decapodiformes; Deoxycytidine; Diagnostic and Statistical Manual of Mental Disorders; Dietary Fiber; Diterpenes; DNA Methylation; Dogs; Double-Blind Method; Drug Design; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Screening Assays, Antitumor; Eicosapentaenoic Acid; Enzyme-Linked Immunosorbent Assay; Epidermis; Escherichia coli; Escherichia coli Infections; Extraintestinal Pathogenic Escherichia coli; Fatty Acids; Fatty Acids, Unsaturated; Fatty Acids, Volatile; Feasibility Studies; Feces; Female; Ferritins; Fluorodeoxyglucose F18; Gastrectomy; Gastrointestinal Microbiome; Gemcitabine; Glomerular Filtration Rate; Glucose; Glycerol; Granulocyte-Macrophage Colony-Stimulating Factor; HeLa Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Hypoxia-Inducible Factor-Proline Dioxygenases; Immunoassay; Immunoglobulin G; India; Infant, Newborn; Infertility; Inflammation; Intensive Care Units; Iron; Iron Deficiencies; Kidney; Lacticaseibacillus rhamnosus; Laurencia; Leukocytes; Lipids; Liver Cirrhosis; Long Interspersed Nucleotide Elements; Longitudinal Studies; Male; Mesenchymal Stem Cells; Methicillin-Resistant Staphylococcus aureus; Mice; Microalgae; Microbial Sensitivity Tests; Microscopy; Middle Aged; Minerals; Molecular Conformation; Molecular Docking Simulation; Molecular Structure; Mycobacterium tuberculosis; Myeloid Cells; Myeloid-Derived Suppressor Cells; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nephropidae; Nicotinic Antagonists; Nitrogen; Obesity; Oxaliplatin; Paclitaxel; Panax; Pancreatic Neoplasms; Pancreatitis; Personality; Personality Disorders; Personality Inventory; Photobioreactors; Plant Extracts; Plasmalogens; Plasmids; Polymorphism, Genetic; Polynesia; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prebiotics; Predictive Value of Tests; Prognosis; Prolyl-Hydroxylase Inhibitors; Rabbits; Radiopharmaceuticals; Rats; Rats, Wistar; Receptors, Nicotinic; Recombinant Proteins; Retrospective Studies; Rifampin; Risk Factors; RNA, Ribosomal, 16S; Salinity; Seaweed; Sensitivity and Specificity; Sepsis; Sesquiterpenes; Severity of Illness Index; Shock, Septic; Silicones; Single Photon Emission Computed Tomography Computed Tomography; Skin; Snails; Solubility; Solvents; Sputum; Staphylococcal Infections; Stomach Neoplasms; Stramenopiles; Structure-Activity Relationship; Technetium Tc 99m Exametazime; Technology; Terpenes; Tuberculosis; Tuberculosis, Multidrug-Resistant; Urinary Catheters; Urinary Tract Infections; Vascular Endothelial Growth Factor A; Virulence Factors; Water; Wound Healing | 2023 |
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Carbapenems; Cefiderocol; Cephalosporins; Drug Resistance, Bacterial; Female; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged; Pneumonia, Bacterial; Sepsis; Urinary Tract Infections; Young Adult | 2021 |
Multicentre randomised controlled trial to investigate usefulness of the rapid diagnostic βLACTA test performed directly on bacterial cell pellets from respiratory, urinary or blood samples for the early de-escalation of carbapenems in septic intensive ca
Topics: beta-Lactam Resistance; beta-Lactamases; Carbapenems; Deprescriptions; Enterobacteriaceae Infections; Equivalence Trials as Topic; Gram-Negative Bacterial Infections; Humans; Intensive Care Units; Microbial Sensitivity Tests; Mortality; Recurrence; Respiratory Tract Infections; Sepsis; Urinary Tract Infections | 2019 |
Activity of doripenem versus comparators in subjects with baseline bacteraemia in six pooled phase 3 clinical trials.
Topics: Anti-Bacterial Agents; Bacteremia; Carbapenems; Cross Infection; Doripenem; Female; Humans; Imipenem; Intraabdominal Infections; Male; Meropenem; Ofloxacin; Pneumonia; Thienamycins; Treatment Outcome; Urinary Tract Infections | 2013 |
A PROspective study on the Usage patterns of Doripenem in the Asia-Pacific region (PROUD study).
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Asia; Carbapenems; Doripenem; Escherichia coli; Escherichia coli Infections; Female; Humans; Intensive Care Units; Intraabdominal Infections; Klebsiella Infections; Klebsiella pneumoniae; Male; Middle Aged; Pneumonia, Ventilator-Associated; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Treatment Outcome; Urinary Tract Infections; Young Adult | 2014 |
Safety and Tolerability of Doripenem in Hospitalized Children With Complicated Intra-Abdominal Infection, Complicated Urinary Tract Infections and Pneumonia.
Topics: Adolescent; Anti-Bacterial Agents; Carbapenems; Child; Child, Preschool; Doripenem; Hospitalization; Humans; Infant; Intraabdominal Infections; Pneumonia, Bacterial; Treatment Outcome; Urinary Tract Infections | 2015 |
Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed,
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenems; Ceftazidime; Drug Combinations; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Female; Gram-Negative Bacteria; Humans; Intraabdominal Infections; Male; Middle Aged; Pseudomonas aeruginosa; Urinary Tract Infections | 2016 |
Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program.
Topics: Adult; Aged; Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Ceftazidime; Doripenem; Drug Combinations; Female; Humans; Male; Middle Aged; Pyelonephritis; Urinary Tract Infections | 2016 |
Efficacy and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: an open-label randomized controlled trial.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Female; Humans; Male; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2017 |
Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteria; Carbapenems; Doripenem; Double-Blind Method; Female; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Prospective Studies; Pyelonephritis; Urinary Tract Infections | 2009 |
Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Carbapenems; Doripenem; Double-Blind Method; Female; Humans; Infusions, Intravenous; Levofloxacin; Male; Ofloxacin; Pyelonephritis; Urinary Tract Infections | 2009 |
Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Bayes Theorem; Carbapenems; Creatinine; Critical Illness; Cross Infection; Doripenem; Female; Humans; Kidney; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Nonlinear Dynamics; Pneumonia, Bacterial; Pyelonephritis; Renal Insufficiency; Urinary Tract Infections; Young Adult | 2010 |
Safety and efficacy of intravenous doripenem for the treatment of complicated urinary tract infections and pyelonephritis.
Topics: Aged; Anti-Infective Agents, Urinary; Carbapenems; Doripenem; Double-Blind Method; Female; Genotype; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Injections, Intravenous; Levofloxacin; Male; Middle Aged; Ofloxacin; Pyelonephritis; Treatment Outcome; Urinary Tract Infections | 2010 |
[Laboratory and clinical studies on SY5555 in pediatrics].
Topics: Adolescent; Bacterial Infections; Carbapenems; Child; Child, Preschool; Female; Half-Life; Humans; Impetigo; Infant; Male; Microbial Sensitivity Tests; Patient Compliance; Respiratory Tract Infections; Urinary Tract Infections | 1995 |
[Clinical studies on SY5555 in the field of pediatrics].
Topics: Administration, Oral; Bacterial Infections; Carbapenems; Child; Child, Preschool; Diarrhea; Eosinophilia; Female; Humans; Infant; Male; Respiratory Tract Infections; Scarlet Fever; Urinary Tract Infections | 1995 |
[Studies on SY5555 in the field of pediatrics].
Topics: Administration, Oral; Bacterial Infections; Carbapenems; Child; Child, Preschool; Female; Half-Life; Humans; Infant; Male; Respiratory Tract Infections; Urinary Tract Infections | 1995 |
[Pharmacokinetic, bacteriological, and clinical studies on SY5555 in children].
Topics: Bacterial Infections; Carbapenems; Child; Child, Preschool; Female; Humans; Infant; Male; Microbial Sensitivity Tests; Respiratory Tract Infections; Urinary Tract Infections | 1995 |
[Clinical studies on SY5555 in pediatric infections].
Topics: Administration, Oral; Adolescent; Bacterial Infections; Carbapenems; Child; Child, Preschool; Female; Humans; Impetigo; Infant; Male; Respiratory Tract Infections; Scarlet Fever; Urinary Tract Infections | 1995 |
[Clinical evaluation of a new oral penem, SY5555, in the pediatric field].
Topics: Administration, Oral; Bacterial Infections; Carbapenems; Child; Child, Preschool; Diarrhea; Female; Humans; Infant; Male; Otitis Media; Respiratory Tract Infections; Urinary Tract Infections | 1995 |
[Bacteriological, pharmacokinetic and clinical studies of SY5555 dry syrup in the pediatric field].
Topics: Absorption; Bacterial Infections; Carbapenems; Child; Child, Preschool; Female; Humans; Infant; Male; Microbial Sensitivity Tests; Respiratory Tract Infections; Skin Diseases, Bacterial; Urinary Tract Infections | 1995 |
[Fundamental and clinical studies on MIC breakpoint of SY5555 for Enterococcus faecalis in complicated urinary tract infections of moderate severity].
Topics: Adult; Carbapenems; Enterococcus faecalis; Gram-Positive Bacterial Infections; Humans; Urinary Tract Infections | 1994 |
Intramuscular meropenem in the treatment of bacterial infections of the urinary and lower respiratory tracts. Italian Intramuscular Meropenem Study Group.
Topics: Bacterial Infections; Carbapenems; Ceftazidime; Cilastatin; Humans; Imipenem; Injections, Intramuscular; Meropenem; Respiratory Tract Infections; Thienamycins; Treatment Outcome; Urinary Tract Infections | 1995 |
Empirical monotherapy with meropenem in serious bacterial infections. Meropenem Study Group.
Topics: Adolescent; Adult; Aged; Amikacin; Bacterial Infections; Carbapenems; Ceftazidime; Community-Acquired Infections; Cross Infection; Drug Therapy, Combination; Drug Tolerance; Hospitalization; Humans; Meropenem; Middle Aged; Respiratory Tract Infections; Sepsis; Thienamycins; Time Factors; Treatment Outcome; Urinary Tract Infections | 1995 |
[Multicenter comparative study of meropenem vs. imipenem in the intramuscular treatment of hospital infections of the urinary tract].
Topics: Adult; Aged; Carbapenems; Chi-Square Distribution; Cilastatin; Cross Infection; Female; Humans; Imipenem; Male; Meropenem; Middle Aged; Protease Inhibitors; Thienamycins; Urinary Tract Infections | 1995 |
Dose finding study on the efficacy and safety of ritipenem in complicated urinary tract infections.
Topics: Adult; Aged; Aged, 80 and over; Carbapenems; Double-Blind Method; Female; Humans; Male; Middle Aged; Urinary Tract Infections | 1995 |
175 other study(ies) available for carbapenems and Urinary Tract Infections
| Article | Year |
|---|---|
Clinical management of cUTI, cIAI, and HABP/VABP attributable to carbapenem-resistant Gram-negative infections in Spain.
Topics: Aftercare; Anti-Bacterial Agents; Carbapenems; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Intraabdominal Infections; Patient Discharge; Pneumonia, Bacterial; Retrospective Studies; Spain; Urinary Tract Infections; Ventilators, Mechanical | 2021 |
Risk factors for isolation of carbapenem-resistant Enterobacterales from normally sterile sites and urine.
Topics: Anti-Bacterial Agents; Carbapenems; Enterobacteriaceae Infections; Escherichia coli; Humans; Risk Factors; Urinary Tract Infections | 2022 |
A clinical prediction tool for extended-spectrum β-lactamase-producing Enterobacteriaceae urinary tract infection.
Topics: Aged; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Humans; Male; Middle Aged; Retrospective Studies; Risk Factors; Urinary Tract Infections | 2022 |
Vancomycin-arginine (STM-001) abrogates ESBL carrier and carbapenem-resistant Escherichia coli burden in a murine complicated urinary tract infection model.
Topics: Animals; Anti-Bacterial Agents; Arginine; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Chromatography, Liquid; Escherichia coli; Escherichia coli Infections; Mice; Microbial Sensitivity Tests; Tandem Mass Spectrometry; Urinary Tract Infections; Vancomycin | 2022 |
In vitro activity of nitroxoline against carbapenem-resistant Acinetobacter baumannii isolated from the urinary tract.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Carbapenems; Ciprofloxacin; Escherichia coli; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Nitroquinolines; Sulfamethoxazole; Trimethoprim; Urinary Tract; Urinary Tract Infections | 2022 |
Carbapenem-resistant gram-negative bacteria in Germany: incidence and distribution among specific infections and mortality: an epidemiological analysis using real-world data.
Topics: Anti-Bacterial Agents; Carbapenems; Ceftazidime; Drug Combinations; Gram-Negative Bacteria; Humans; Incidence; Urinary Tract Infections | 2022 |
Management of antibacterial therapy of infectious and inflammatory diseases of the urinary tract in children and regional peculiarities during the COVID-19 pandemic.
Topics: Adolescent; Anti-Bacterial Agents; Carbapenems; Child; Child, Preschool; COVID-19 Drug Treatment; Doxycycline; Humans; Imipenem; Infant; Infant, Newborn; Levofloxacin; Microbial Sensitivity Tests; Pandemics; Urinary Tract; Urinary Tract Infections | 2022 |
Activity of mecillinam against carbapenem-resistant Enterobacterales.
Topics: Amdinocillin; Bacterial Proteins; beta-Lactamases; Carbapenems; Enterobacteriaceae Infections; Escherichia coli; Humans; Microbial Sensitivity Tests; Urinary Tract Infections | 2022 |
[Tebipenem pivoxil : Oral carbapenem for treatment of complicated urinary tract infections].
Topics: Carbapenems; Humans; Urinary Tract Infections | 2022 |
Cefoxitin-based combination for ESBL-producing Enterobacteriaceae endocarditis.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefoxitin; Cilastatin, Imipenem Drug Combination; Ciprofloxacin; Endocarditis; Enterobacteriaceae; Escherichia coli; Escherichia coli Infections; Fosfomycin; Humans; Microbial Sensitivity Tests; Urinary Tract Infections | 2022 |
Evolution of antibiotic treatments for healthcare-associated infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae in France.
Topics: Aminoglycosides; Amoxicillin; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Clavulanic Acid; Cross Infection; Delivery of Health Care; Enterobacteriaceae; Enterobacteriaceae Infections; France; Humans; Nitrofurantoin; Ofloxacin; Penicillins; Urinary Tract Infections | 2022 |
Prevalence, etiology and antibiotic resistance patterns of community-acquired urinary tract infections in Dhaka, Bangladesh.
Topics: Adult; Anti-Bacterial Agents; Bangladesh; Carbapenems; Cephalosporins; Coagulase; Community-Acquired Infections; Cross-Sectional Studies; Drug Resistance, Microbial; Enterococcus; Escherichia coli; Female; Fluoroquinolones; Humans; Klebsiella; Macrolides; Male; Penicillins; Prevalence; Urinary Tract Infections | 2022 |
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Humans; United States; Urinary Tract Infections | 2022 |
Resistance Pattern in Mostly Gram-negative Bacteria Causing Urinary Tract Infections.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Carbapenems; Cephalosporins; Cross-Sectional Studies; Drug Resistance, Bacterial; Escherichia coli; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Retrospective Studies; Urinary Tract Infections | 2023 |
Genetic Diversity, Carbapenem Resistance Genes, and Biofilm Formation in UPEC Isolated from Patients with Catheter-Associated Urinary Tract Infection in North of Iran.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactamases; Biofilms; Carbapenems; Catheters; Cross-Sectional Studies; Edetic Acid; Genetic Variation; Humans; Iran; Nalidixic Acid; Trimethoprim, Sulfamethoxazole Drug Combination; Urinary Tract Infections | 2022 |
Assessment of ß-lactams and Carbapenems Antimicrobials Resistance in
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Ceftazidime; Cephamycins; Cloxacillin; Humans; Iraq; Klebsiella oxytoca; Lactams; Microbial Sensitivity Tests; Piperacillin; Urinary Tract Infections | 2022 |
Sitafloxacin pharmacokinetics/pharmacodynamics against multidrug-resistant bacteria in a dynamic urinary tract infection in vitro model.
Topics: Anti-Bacterial Agents; Bacteria; Carbapenems; Escherichia coli; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Urinary Tract Infections; Vancomycin | 2022 |
Efficacy and safety of intravenous fosfomycin for the treatment of carbapenem-resistant
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Fosfomycin; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Pneumonia; Urinary Tract Infections | 2023 |
A case report: Intermittent catheterization combined with rehabilitation in the treatment of carbapenem-resistant
Topics: Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Catheter-Related Infections; Catheterization; Catheters; Humans; Klebsiella pneumoniae; Urinary Tract Infections | 2022 |
Magnitude and antimicrobial susceptibility profiles of Gram-Negative bacterial isolates among patients suspected of urinary tract infections in Arba Minch General Hospital, southern Ethiopia.
Topics: Anti-Bacterial Agents; Carbapenems; Cross-Sectional Studies; Ethiopia; Female; Gram-Negative Bacteria; Hospitals, General; Humans; Male; Microbial Sensitivity Tests; Urinary Tract Infections | 2022 |
Clinical and cost-effectiveness analysis of carbapenems versus ciprofloxacin in the treatment of urinary tract infections due to extended spectrum β-lactamase-producing Enterobacterales.
Topics: Adult; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Ciprofloxacin; Cost-Effectiveness Analysis; Female; Humans; Pregnancy; Retrospective Studies; Urinary Tract Infections | 2023 |
Comparison of the relative efficacy of β-lactam/β-lactamase inhibitors and carbapenems in the treatment of complicated urinary tract infections caused by ceftriaxone-non-susceptible Enterobacterales: a multicentre retrospective observational cohort study.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Ceftriaxone; Enterobacteriaceae; Enterobacteriaceae Infections; Gammaproteobacteria; Humans; Lactams; Retrospective Studies; Urinary Tract Infections | 2023 |
Co-occurrence of blaNDM-1, rmtC, and mcr-9 in multidrug-resistant Enterobacter kobei strain isolated from an infant with urinary tract infection.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Colistin; Escherichia coli; Escherichia coli Proteins; Humans; Infant; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Urinary Tract Infections | 2023 |
Efficacy of carbapenems versus alternative antimicrobials for treating complicated urinary tract infections caused by antimicrobial-resistant Gram-negative bacteria: protocol for a systematic review and meta-analysis.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Gram-Negative Bacteria; Humans; Meta-Analysis as Topic; Systematic Reviews as Topic; Urinary Tract Infections | 2023 |
Microbiological Spectrum and Antibiogram of Urinary Tract Infection in a Tertiary Care Center from the Kingdom of Bahrain.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bahrain; beta-Lactamases; Carbapenems; Ciprofloxacin; Escherichia coli; Female; Humans; Klebsiella pneumoniae; Levofloxacin; Male; Microbial Sensitivity Tests; Retrospective Studies; Tertiary Care Centers; Trimethoprim, Sulfamethoxazole Drug Combination; Urinary Tract Infections | 2022 |
Risk of relapse and readmission among hospitalized adults with carbapenem non-susceptible gram-negative infections.
Topics: Adult; Aftercare; Anti-Bacterial Agents; Carbapenems; Gram-Negative Bacterial Infections; Humans; Patient Discharge; Patient Readmission; Retrospective Studies; Urinary Tract Infections | 2023 |
Breaking Antimicrobial Resistance: High-Dose Amoxicillin with Clavulanic Acid for Urinary Tract Infections Due to Extended-Spectrum Beta-Lactamase (ESBL)-Producing Klebsiella pneumoniae.
Topics: Amoxicillin; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Clavulanic Acid; Drug Resistance, Bacterial; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Urinary Tract Infections | 2023 |
Population Pharmacokinetic Analyses for Tebipenem after Oral Administration of Pro-Drug Tebipenem Pivoxil Hydrobromide.
Topics: Administration, Oral; Anti-Bacterial Agents; Carbapenems; Humans; Monobactams; Prodrugs; Pyelonephritis; Urinary Tract Infections | 2023 |
Efficacy and safety of piperacillin-tazobactam compared with meropenem in treating complicated urinary tract infections including acute pyelonephritis due to extended-spectrum β-lactamase-producing
Topics: Adult; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pyelonephritis; Retrospective Studies; Urinary Tract Infections | 2023 |
Budget impact analysis of temocillin insurance coverage for urinary tract infections caused by ESBL-producing pathogens in Iran.
Topics: Anti-Bacterial Agents; Carbapenems; Female; Humans; Hydrolases; Insurance Coverage; Iran; Urinary Tract Infections | 2023 |
Changing Genotypic Distribution, Antimicrobial Susceptibilities, and Risk Factors of Urinary Tract Infection Caused by Carbapenemase-Producing
Topics: Anti-Bacterial Agents; Carbapenems; Cross Infection; Genotype; Humans; Pseudomonas aeruginosa; Risk Factors; Urinary Tract Infections | 2024 |
Phenotyping and Genotyping Evaluation of
Topics: Anti-Bacterial Agents; Carbapenems; Escherichia coli; Genotype; Humans; Iraq; Neoplasms; Urinary Tract Infections | 2023 |
Efficacy of cefoxitin versus carbapenem in febrile male urinary tract infections caused by extended spectrum beta-lactamase-producing Escherichia coli: a multicenter retrospective cohort study with propensity score analysis.
Topics: Aged; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefoxitin; Escherichia coli; Escherichia coli Infections; Fever; Humans; Male; Middle Aged; Propensity Score; Retrospective Studies; Urinary Tract Infections | 2020 |
Direct medical costs of urinary tract infections by Gram-negative bacilli resistant to beta-lactams in a tertiary care hospital in Medellín, Colombia
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Carbapenems; Cephalosporins; Cohort Studies; Colombia; Cross Infection; Diagnostic Imaging; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacteria; Health Expenditures; Hospitalization; Hospitals, Urban; Humans; Male; Middle Aged; Tertiary Care Centers; Urinary Tract Infections | 2019 |
Carbapenem/β-lactamase inhibitor combination in complicated urinary tract infection.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Humans; Urinary Tract Infections | 2020 |
Genomic analysis of two drug-resistant clinical Morganella morganii strains isolated from UTI patients in Pretoria, South Africa.
Topics: Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae Infections; Female; Genome, Bacterial; Genomics; Humans; Integrons; Male; Microbial Sensitivity Tests; Middle Aged; Morganella morganii; Phylogeny; Plasmids; South Africa; Urinary Tract Infections | 2020 |
Carbapenem-Containing Combination Antibiotic Therapy against Carbapenem-Resistant Uropathogenic
Topics: Anti-Bacterial Agents; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Drug Resistance, Multiple, Bacterial; Ertapenem; Fosfomycin; Humans; Levofloxacin; Microbial Sensitivity Tests; Rifampin; Urinary Tract Infections | 2019 |
Pharmacist recommendations for carbapenem de-escalation in urinary tract infection within an antimicrobial stewardship program.
Topics: Aged; Aged, 80 and over; Antimicrobial Stewardship; Carbapenems; Cross Infection; Female; Humans; Length of Stay; Male; Middle Aged; Pharmacists; Prospective Studies; Urinary Tract Infections | 2020 |
Aminoglycoside versus carbapenem or piperacillin/tazobactam treatment for bloodstream infections of urinary source caused by Gram-negative ESBL-producing Enterobacteriaceae.
Topics: Aged; Aminoglycosides; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Carbapenems; Enterobacteriaceae; Enterobacteriaceae Infections; Escherichia coli; Humans; Piperacillin, Tazobactam Drug Combination; Pyelonephritis; Retrospective Studies; Urinary Tract Infections | 2020 |
Prevalence of carbapenem-hydrolyzing OXA-type β-lactamases among Acinetobacter baumannii in patients with severe urinary tract infection.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Drug Resistance, Multiple, Bacterial; Genotype; Humans; Hydrolysis; India; Microbial Sensitivity Tests; Plasmids; Prevalence; Severity of Illness Index; Urinary Tract Infections | 2019 |
Carbapenem-resistant Klebsiella pneumonia infection outbreak in a tertiary urology clinic: analysis of influencing factors with a controlled trial
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Disease Outbreaks; Humans; Klebsiella Infections; Klebsiella pneumoniae; Middle Aged; Urinary Tract Infections | 2020 |
Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant
Topics: Aged; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Boronic Acids; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Ceftazidime; Cohort Studies; Drug Combinations; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae Infections; Female; Humans; Male; Meropenem; Middle Aged; Retrospective Studies; Treatment Outcome; Urinary Tract Infections | 2020 |
Adaptive evolution of virulence and persistence in carbapenem-resistant Klebsiella pneumoniae.
Topics: Adaptation, Biological; Adult; Animals; Bacterial Capsules; beta-Lactam Resistance; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Cells, Cultured; Evolution, Molecular; Female; Genome, Bacterial; Humans; Klebsiella Infections; Klebsiella pneumoniae; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Transgenic; Phylogeny; Polymorphism, Single Nucleotide; Urinary Tract Infections; Virulence; Zebrafish | 2020 |
Extensively Drug-resistant
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Bacterial Proteins; Bacterial Typing Techniques; beta-Lactamases; Carbapenems; Cats; Drug Resistance, Multiple, Bacterial; Female; Microbial Sensitivity Tests; Multilocus Sequence Typing; Pakistan; Urinary Tract Infections | 2020 |
Topics: Adult; Animals; Anti-Bacterial Agents; Carbapenems; Humans; Meropenem; Mice; Urinary Tract Infections | 2020 |
An amphipathic peptide with antibiotic activity against multidrug-resistant Gram-negative bacteria.
Topics: Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Carbapenems; Cell Membrane Permeability; Colistin; Disease Models, Animal; Drug Discovery; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacteria; Helminth Proteins; Humans; Male; Mice; Microbial Sensitivity Tests; Peritonitis; Pneumonia; Urinary Tract Infections | 2020 |
Genomic features of a carbapenem-resistant OXA-219-positive Acinetobacter baumannii of international ST15 (CC15) from a patient with community-onset urinary tract infection in Chilean Patagonia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Carbapenems; Chile; Genomics; Humans; Multilocus Sequence Typing; Urinary Tract Infections | 2020 |
Impact of reflex fosfomycin susceptibility testing on the utilization of carbapenems for definitive extended-spectrum β-lactamase Escherichia coli urinary tract infection treatment.
Topics: Aged; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cohort Studies; Escherichia coli; Escherichia coli Infections; Female; Florida; Fosfomycin; Humans; Male; Microbial Sensitivity Tests; Pharmacy Service, Hospital; Retrospective Studies; Urinary Tract Infections | 2020 |
Factors associated with successful completion of outpatient parenteral antibiotic therapy in an area with a high prevalence of multidrug-resistant bacteria: 30-day hospital admission and mortality rates.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Brazil; Carbapenems; Drug Resistance, Multiple, Bacterial; Female; Humans; Klebsiella pneumoniae; Male; Middle Aged; Mortality; Outpatients; Patient Admission; Pneumonia; Prevalence; Treatment Outcome; Urinary Tract Infections | 2020 |
Efficacy of β-lactam/β-lactamase inhibitors to treat extended-spectrum beta-lactamase-producing Enterobacterales bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENT-SOT Project).
Topics: Anti-Bacterial Agents; Bacteremia; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Enterobacteriaceae Infections; Humans; Kidney Transplantation; Lactams; Retrospective Studies; Urinary Tract Infections | 2021 |
Multiple antimicrobial resistance and outcomes among hospitalized patients with complicated urinary tract infections in the US, 2013-2018: a retrospective cohort study.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Chronic Disease; Drug Combinations; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Hospitalization; Humans; Male; Middle Aged; Retrospective Studies; Risk Factors; Sulfadoxine; Trimethoprim; United States; Urinary Tract Infections | 2021 |
Temocillin versus carbapenems for urinary tract infection due to ESBL-producing Enterobacteriaceae: a multicenter matched case-control study.
Topics: Aged; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillins; Retrospective Studies; Treatment Outcome; Urinary Tract Infections | 2021 |
Burden of illness in US hospitals due to carbapenem-resistant Gram-negative urinary tract infections in patients with or without bacteraemia.
Topics: Aged; Aged, 80 and over; Bacteremia; Carbapenems; Cost of Illness; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Hospitalization; Humans; Male; Middle Aged; Retrospective Studies; Risk Factors; United States; Urinary Tract Infections | 2021 |
Genetic Background and Antibiotic Resistance Profiles of
Topics: Bacteriuria; beta-Lactamases; Carbapenems; Drug Resistance, Microbial; Gastrointestinal Tract; Hospitals; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Multilocus Sequence Typing; Phylogeny; Plasmids; Polymorphism, Single Nucleotide; Urinary Tract Infections | 2021 |
Community-onset carbapenem-resistant Klebsiella pneumoniae urinary tract infections in infancy following NICU hospitalisation.
Topics: Age Factors; Carbapenems; Cohort Studies; Community-Acquired Infections; Databases, Factual; Drug Resistance, Microbial; Female; Greece; Hospitalization; Humans; Incidence; Infant; Infant, Newborn; Intensive Care Units, Neonatal; Klebsiella pneumoniae; Male; Prognosis; Retrospective Studies; Risk Assessment; Sex Factors; Urinary Tract Infections | 2017 |
EUropean prospective cohort study on
Topics: Anti-Bacterial Agents; Bacteremia; Carbapenems; Case-Control Studies; Cause of Death; Cohort Studies; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Europe; Hospitalization; Humans; Intraabdominal Infections; Microbial Sensitivity Tests; Mortality; Pneumonia, Bacterial; Prospective Studies; Treatment Outcome; Urinary Tract Infections | 2017 |
Tigecycline resistance among carbapenem-resistant Klebsiella Pneumoniae: Clinical characteristics and expression levels of efflux pump genes.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Biological Transport; Carbapenems; Drug Resistance, Bacterial; Female; Genes, Bacterial; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Middle Aged; Minocycline; Real-Time Polymerase Chain Reaction; Tigecycline; Urinary Tract Infections | 2017 |
Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Drug Resistance, Bacterial; Enterobacteriaceae Infections; Female; Health Care Costs; Hospital Mortality; Hospitalization; Humans; Inappropriate Prescribing; Length of Stay; Male; Middle Aged; Pneumonia; Prevalence; Retrospective Studies; Risk Factors; Sepsis; Treatment Outcome; Urinary Tract Infections | 2017 |
[Carbapenem resistance in Pseudomonas aeruginosa isolated from urine cultures: prevalence and risk factors].
Topics: Aged; Aged, 80 and over; Carbapenems; Cardiomyopathy, Dilated; Drug Resistance, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Prevalence; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Urinary Tract Infections; Urine | 2017 |
Efficacy of non-carbapenem antibiotics for pediatric patients with first febrile urinary tract infection due to extended-spectrum beta-lactamase-producing Escherichia coli.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Child, Preschool; Escherichia coli; Escherichia coli Infections; Female; Fever; Humans; Infant; Japan; Male; Retrospective Studies; Urinary Tract Infections | 2017 |
Evaluation of Carbapenem Resistance Mechanisms and Its Association with Pseudomonas aeruginosa Infections in the Northwest of Iran.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Clone Cells; Female; Gene Expression Regulation, Bacterial; Hospitalization; Humans; Iran; Isoenzymes; Male; Microbial Sensitivity Tests; Middle Aged; Molecular Epidemiology; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Urinary Tract Infections | 2018 |
Clinical outcomes associated with carbapenem resistant Klebsiella pneumoniae (CRKP) in abdominal solid organ transplant (SOT) recipients.
Topics: Carbapenems; Enterobacteriaceae; Humans; Incidence; Kidney Transplantation; Klebsiella Infections; Klebsiella pneumoniae; Risk Factors; Urinary Tract Infections | 2018 |
In-vivo loss of carbapenem resistance by extensively drug-resistant Klebsiella pneumoniae during treatment via porin expression modification.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Female; Gene Expression Regulation, Bacterial; Genome, Bacterial; Humans; Klebsiella Infections; Klebsiella pneumoniae; Middle Aged; Mutation; Nitrobenzenes; Penicillins; Porins; Tetracyclines; Urinary Tract Infections | 2017 |
Pharmacokinetic/Pharmacodynamic Analysis for Doripenem Regimens in Intensive Care Unit Patient.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bayes Theorem; Carbapenems; Doripenem; Female; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Monte Carlo Method; Prostatitis; Urinary Tract Infections; Young Adult | 2017 |
Risk factors for carbapenem-nonsusceptible Pseudomonas aeruginosa: Case-control study.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Case-Control Studies; Female; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Risk Factors; Urinary Tract Infections | 2017 |
Cefepime versus carbapenems for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing enterobacteriaceae.
Topics: Aged; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefepime; Cephalosporins; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Humans; Male; Microbial Sensitivity Tests; Retrospective Studies; Urinary Tract Infections | 2018 |
Reducing Carbapenem Exposure: Extended-Spectrum β-Lactamase Catheter-Associated Urinary Tract Infection Management.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Carbapenems; Enterobacteriaceae; Female; Humans; Male; Middle Aged; United States; Urinary Tract Infections | 2017 |
Impact of Penicillin Allergy on Time to First Dose of Antimicrobial Therapy and Clinical Outcomes.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Carbapenems; Drug Hypersensitivity; Emergency Service, Hospital; Female; Hospitalization; Humans; Male; Middle Aged; Patient Readmission; Penicillins; Pneumonia; Retrospective Studies; Sepsis; Urinary Tract Infections | 2017 |
"Double carbapenem" and oral fosfomycin for the treatment of complicated urinary tract infections caused by bla
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Enterobacteriaceae; Enterobacteriaceae Infections; Fosfomycin; Humans; Kidney Transplantation; Male; Microbial Sensitivity Tests; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2018 |
Copper Ions and Coordination Complexes as Novel Carbapenem Adjuvants.
Topics: Adjuvants, Pharmaceutic; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Coordination Complexes; Copper; Ertapenem; Escherichia coli; Humans; Ions; Meropenem; Microbial Sensitivity Tests; Urinary Tract Infections | 2018 |
New Delhi metallo-β-lactamase - type carbapenemases producing
Topics: beta-Lactamases; Carbapenems; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Urinary Tract Infections | 2017 |
Epidemiology of Carbapenem-Resistant Enterobacteriaceae Infections: Report from the China CRE Network.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; China; Citrobacter freundii; Enterobacter cloacae; Enterobacteriaceae Infections; Escherichia coli; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Polymyxin B; Urinary Tract Infections | 2018 |
Febrile urinary-tract infection due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in children: A French prospective multicenter study.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Child; Child, Preschool; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Fever; France; Humans; Infant; Infant, Newborn; Male; Microbial Sensitivity Tests; Prospective Studies; Risk Factors; Urinary Tract Infections | 2018 |
Importance of Site of Infection and Antibiotic Selection in the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Sepsis.
Topics: Adult; Aged; Carbapenems; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Sepsis; Urinary Tract Infections | 2018 |
Extended-spectrum β-lactamase-producing Enterobacteriaceae, national study of antimicrobial treatment for pediatric urinary tract infection.
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Child; Child, Preschool; Cross-Sectional Studies; Cystitis; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Female; France; Hospitals, University; Humans; Inappropriate Prescribing; Male; Practice Patterns, Physicians'; Pyelonephritis; Retrospective Studies; Secondary Care Centers; Surveys and Questionnaires; Urinary Tract Infections | 2018 |
Which non-carbapenem antibiotics are active against extended-spectrum β-lactamase-producing Enterobacteriaceae?
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Enterobacteriaceae; Enterobacteriaceae Infections; Escherichia coli; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam; Urinary Tract Infections | 2018 |
Healthcare-Associated Infections after Lower Urinary Tract Endoscopic Surgery: Analysis of Risk Factors, Associated Microorganisms and Patterns of Antibiotic Resistance.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Carbapenems; Comorbidity; Cross Infection; Drug Resistance, Bacterial; Endoscopy; Enterobacteriaceae; Enterococcus; Escherichia coli; Female; Fluoroquinolones; Humans; Incidence; Male; Middle Aged; Multivariate Analysis; Postoperative Period; Prospective Studies; Pseudomonas aeruginosa; Risk Factors; Tertiary Care Centers; Urinary Catheters; Urinary Tract; Urinary Tract Infections; Young Adult | 2018 |
Does the urinary tract infection caused by carbapenem-resistant Gram-negative bacilli impact the outcome of kidney transplant recipients?
Topics: Age Factors; beta-Lactam Resistance; Carbapenems; Delayed Graft Function; Female; Follow-Up Studies; Graft Rejection; Gram-Negative Bacteria; Humans; Incidence; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Retrospective Studies; Risk Factors; Sex Factors; Survival Analysis; Urinary Tract Infections | 2018 |
Development and validation of a bedside instrument to predict carbapenem resistance among gram-negative pathogens in complicated urinary tract infections.
Topics: Aged; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Catheter-Related Infections; Cross Infection; Female; Gram-Negative Bacterial Infections; Humans; Logistic Models; Male; Middle Aged; Models, Theoretical; Prognosis; Retrospective Studies; Risk Assessment; Severity of Illness Index; United States; Urinary Tract Infections | 2018 |
Characterization of SPR994, an Orally Available Carbapenem, with Activity Comparable to Intravenously Administered Carbapenems.
Topics: Administration, Intravenous; Administration, Oral; Adult; Animals; Anti-Bacterial Agents; Biological Availability; Carbapenems; Disease Models, Animal; Gastrointestinal Microbiome; Gram-Negative Bacteria; Gram-Positive Bacteria; Hospitalization; Humans; Male; Mice; Microbial Sensitivity Tests; Treatment Outcome; Urinary Tract Infections | 2018 |
NDM-1-producing Enterobacter aerogenes isolated from a patient with a JJ ureteric stent in situ.
Topics: Aged; beta-Lactamases; Carbapenems; Cross Infection; Drug Resistance, Multiple, Bacterial; Enterobacter aerogenes; Enterobacteriaceae Infections; Female; Humans; Microbial Sensitivity Tests; Stents; Ureteral Obstruction; Urinary Tract Infections | 2019 |
Occurrence and characterization of carbapenem-resistant Gram-negative bacilli: A collaborative study of antibiotic-resistant bacteria between Indonesia and Japan.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Female; Humans; Indonesia; Japan; Male; Prospective Studies; Urinary Tract Infections | 2018 |
Molecular characteristics of carbapenem-resistant Pseudomonas aeruginosa isolated from urine in Hyogo, Japan.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Female; Humans; Japan; Male; Middle Aged; Multilocus Sequence Typing; Polymerase Chain Reaction; Pseudomonas aeruginosa; Urinary Tract Infections | 2019 |
Attributable clinical and economic burden of carbapenem-non-susceptible Gram-negative infections in patients hospitalized with complicated urinary tract infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Cost of Illness; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Health Care Costs; Humans; Length of Stay; Male; Middle Aged; Prevalence; Survival Analysis; Urinary Tract Infections; Young Adult | 2019 |
Novel Antibiotics in the Treatment of Urinary Tract Infections.
Topics: Aminoglycosides; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Clinical Trials as Topic; Cystitis; Drug Resistance, Bacterial; Drug Therapy, Combination; Drug Utilization; Fluoroquinolones; Gram-Negative Bacterial Infections; Humans; Iatrogenic Disease; Tetracyclines; Urinary Tract Infections | 2019 |
Cost-effectiveness analysis of ceftazidime/avibactam compared to imipenem as empirical treatment for complicated urinary tract infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Ceftazidime; Colistin; Cost-Benefit Analysis; Drug Combinations; Europe; Gram-Negative Bacteria; Humans; Imipenem; Length of Stay; National Health Programs; United States; Urinary Tract Infections | 2019 |
Retrospective analysis of colistin-resistant bacteria in a tertiary care centre in India.
Topics: Adult; Aged; Aged, 80 and over; Bacterial Infections; beta-Lactamases; Carbapenems; Colistin; Drug Resistance, Bacterial; Enterobacteriaceae; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Tertiary Care Centers; Urinary Tract Infections | 2019 |
Uropathogens and antibiotic resistance in the community and hospital-induced urinary tract infected children.
Topics: Adolescent; Amikacin; Ampicillin; Anti-Bacterial Agents; Carbapenems; Child; Child, Preschool; Drug Resistance, Bacterial; Escherichia coli; Female; Humans; Infant; Infant, Newborn; Inpatients; Klebsiella; Male; Microbial Sensitivity Tests; Outpatients; Proteus; Retrospective Studies; Trimethoprim, Sulfamethoxazole Drug Combination; Turkey; Urinary Tract Infections | 2020 |
Noncarbapenems for the Treatment of Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Bacteria.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Enterobacteriaceae; Female; Humans; Male; Microbial Sensitivity Tests; Retrospective Studies; Urinary Tract Infections | 2019 |
Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant Klebsiella pneumoniae.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Doripenem; Drug Combinations; Drug Resistance, Bacterial; Ertapenem; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Middle Aged; Thienamycins; Treatment Outcome; Urinary Tract Infections | 2013 |
[Increasing prevalence of fosfomycin resistance in extended-spectrum-beta-lactamase-producing Escherichia coli urinary isolates (2005-2009-2011)].
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Fosfomycin; Humans; Microbial Sensitivity Tests; Prevalence; Urinary Tract Infections; Urine | 2013 |
Carbapenem resistance and mortality in institutionalized elderly with urinary infection.
Topics: Aged; Anti-Bacterial Agents; Carbapenems; Cohort Studies; Drug Resistance; Female; Humans; Male; Nursing Homes; Patient Transfer; Regression Analysis; Risk Factors; Urinary Catheterization; Urinary Tract Infections | 2013 |
Fosfomycin activity versus carbapenem-resistant Enterobacteriaceae and vancomycin-resistant Enterococcus, Detroit, 2008-10.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Enterococcus; Fosfomycin; Gram-Positive Bacterial Infections; Humans; Michigan; Microbial Sensitivity Tests; Urinary Tract Infections; Vancomycin Resistance | 2013 |
Carbapenem de-escalation therapy in a resource-limited setting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Female; Gentian Violet; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Lung Diseases; Male; Middle Aged; Phenazines; Referral and Consultation; Shock, Septic; Thailand; Urinary Tract Infections; Young Adult | 2013 |
First report of OXA-23-mediated carbapenem resistance in sequence type 2 multidrug-resistant Acinetobacter baumannii associated with urinary tract infection in a cat.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cat Diseases; Cats; Drug Resistance, Multiple, Bacterial; Gene Expression; Urinary Tract Infections | 2014 |
Epidemiology and clinical outcomes of patients with carbapenem-resistant Klebsiella pneumoniae bacteriuria.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteriuria; Carbapenems; Cohort Studies; Doxycycline; Female; Hospitalization; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Middle Aged; Multivariate Analysis; Pennsylvania; Retrospective Studies; Treatment Outcome; Urinary Tract Infections; Young Adult | 2014 |
Alternatives to carbapenems for infections caused by ESBL-producing Enterobacteriaceae.
Topics: Adult; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Cephamycins; Child; Child, Preschool; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Humans; Male; Retrospective Studies; Sepsis; Urinary Tract Infections | 2014 |
Pharmacological study of cefoxitin as an alternative antibiotic therapy to carbapenems in treatment of urinary tract infections due to extended-spectrum-β-lactamase-producing Escherichia coli.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Cefoxitin; Drug Administration Schedule; Drug Dosage Calculations; Escherichia coli; Escherichia coli Infections; Gene Expression; Humans; Microbial Sensitivity Tests; Models, Statistical; Pyelonephritis; Urinary Tract Infections | 2014 |
Pseudo-outbreak of Oxa-23-mediated carbapenem-resistant Acinetobacter baumannii in urinary tract infections caused by an automated urine analyzer.
Topics: Acinetobacter baumannii; Acinetobacter Infections; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Disease Outbreaks; Equipment Contamination; Humans; Urinalysis; Urinary Tract Infections | 2014 |
Carbapenem-resistant Klebsiella pneumoniae urinary tract infection following solid organ transplantation.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cohort Studies; Drug Resistance, Bacterial; Female; Humans; Intensive Care Units; Klebsiella Infections; Klebsiella pneumoniae; Length of Stay; Logistic Models; Male; Microbial Sensitivity Tests; Middle Aged; Ohio; Organ Transplantation; Retrospective Studies; Treatment Outcome; Urinary Tract Infections | 2015 |
A prediction tool for nosocomial multi-drug Resistant Gram-Negative Bacilli infections in critically ill patients - prospective observational study.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Aged; Anti-Bacterial Agents; Bacteremia; Carbapenems; Cohort Studies; Critical Illness; Cross Infection; Decision Support Techniques; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Intensive Care Units; Kidney Failure, Chronic; Klebsiella Infections; Klebsiella pneumoniae; Length of Stay; Logistic Models; Male; Middle Aged; Pneumonia, Bacterial; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Renal Dialysis; Risk Factors; Surgical Procedures, Operative; Systemic Inflammatory Response Syndrome; Urinary Tract Infections | 2014 |
Efficacy of empirical therapy with non-carbapenems for urinary tract infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Retrospective Studies; Urinary Tract Infections | 2014 |
Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Cohort Studies; Female; Genotype; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Middle Aged; Molecular Typing; Prospective Studies; Treatment Outcome; Urinary Tract Infections | 2015 |
Molecular analysis of the integrons of metallo-β-lactamase-producing Pseudomonas aeruginosa isolates collected by nationwide surveillance programs across Japan.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; DNA, Bacterial; Electrophoresis, Gel, Pulsed-Field; Epidemiological Monitoring; Gene Expression; Genotype; Integrons; Japan; Microbial Sensitivity Tests; Molecular Epidemiology; Pseudomonas aeruginosa; Pseudomonas Infections; Urinary Tract Infections | 2015 |
Characterization of Multidrug Resistant Extended-Spectrum Beta-Lactamase-Producing Escherichia coli among Uropathogens of Pediatrics in North of Iran.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Iran; Male; Urinary Tract Infections | 2015 |
Impact of carbapenem resistance on epidemiology and outcomes of nonbacteremic Klebsiella pneumoniae infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Middle Aged; Pneumonia, Bacterial; Retrospective Studies; Risk Factors; Treatment Outcome; Urinary Tract Infections; Young Adult | 2015 |
Molecular characterization of carbapenem-resistant Pseudomonas aeruginosa strains isolated from patients with urinary tract infections in Southern Poland.
Topics: Adolescent; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Cluster Analysis; Female; Genes, Bacterial; Genetic Variation; Genotype; Humans; Infant; Male; Middle Aged; Molecular Epidemiology; Multilocus Sequence Typing; Poland; Pseudomonas aeruginosa; Pseudomonas Infections; Urinary Tract Infections | 2015 |
Occurrence of blaNDM-₁ & absence of blaKPC genes encoding carbapenem resistance in uropathogens from a tertiary care centre from north India.
Topics: Bacterial Proteins; beta-Lactamases; Carbapenems; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; India; Microbial Sensitivity Tests; Urinary Tract Infections | 2015 |
Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
Topics: Aminoglycosides; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Escherichia coli Infections; Female; Humans; Infant; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Pyelonephritis; Republic of Korea; Retrospective Studies; Treatment Outcome; Urinary Tract Infections; Uropathogenic Escherichia coli | 2015 |
Ertapenem-Containing Double-Carbapenem Therapy for Treatment of Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactams; Carbapenems; Ertapenem; Female; Humans; Intraabdominal Infections; Klebsiella Infections; Klebsiella pneumoniae; Length of Stay; Male; Middle Aged; Pneumonia, Bacterial; Survival Analysis; Treatment Outcome; Urinary Tract Infections | 2016 |
Association of Risk Factors, Antimicrobial Resistance Trends and Occurrence of blaTEM, bla SHV and blaCTX M in Escherichia coli Causing Bacteremia.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Carbapenems; Diabetes Complications; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Male; Middle Aged; Phenotype; Polymerase Chain Reaction; Prospective Studies; Risk Factors; Urinary Tract Infections | 2016 |
[A Case of Severe Chronic Active Epstein-Barr Virus Infection with Aplastic Anemia and Hepatitis].
Topics: Aged; Anemia, Aplastic; Carbapenems; Chronic Disease; DNA, Viral; Epstein-Barr Virus Infections; Female; Hepatitis; Herpesvirus 4, Human; Humans; Real-Time Polymerase Chain Reaction; Severity of Illness Index; Urinary Tract Infections | 2016 |
[Clinical features and antibiotic resistance of Escherichia coli bloodstream infections in children].
Topics: Adolescent; Bacteremia; beta-Lactamases; Carbapenems; Child; Child, Preschool; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Infant; Infant, Newborn; Male; Meningitis, Bacterial; Microbial Sensitivity Tests; Pneumonia; Urinary Tract Infections | 2016 |
[OFF-LABEL DRUG USAGE IN THE TREATMENT OF URINARY TRACT INFECTION OF NEWBORNS].
Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporins; Drug Hypersensitivity; Drug Labeling; Dysbiosis; Female; Humans; Infant; Infant, Newborn; Length of Stay; Macrolides; Male; Moscow; Off-Label Use; Sulfonamides; Urinary Tract Infections | 2015 |
Outbreak of IMP-producing carbapenem-resistant Enterobacter gergoviae among kidney transplant recipients.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Case-Control Studies; Disease Outbreaks; Enterobacter; Enterobacteriaceae Infections; Female; Humans; Kidney Transplantation; Male; Middle Aged; Sequence Analysis, DNA; Transplant Recipients; Urinary Tract Infections; Young Adult | 2016 |
Predicting Antibiotic Resistance in Urinary Tract Infection Patients with Prior Urine Cultures.
Topics: Aged; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Humans; Male; Retrospective Studies; Urinary Tract Infections; Urine | 2016 |
Surveillance of antibiotic susceptibility in a Swedish Burn Center 1994-2012.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adolescent; Adult; Anti-Bacterial Agents; Bacteremia; Burn Units; Burns; Carbapenems; Drug Resistance, Bacterial; Female; Gram-Negative Bacterial Infections; Humans; Klebsiella; Klebsiella Infections; Linear Models; Logistic Models; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Staphylococcal Infections; Sweden; Urinary Tract Infections; Wound Infection; Young Adult | 2016 |
Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Carbapenems; Cefmetazole; Drug Resistance, Bacterial; Enterobacteriaceae; Escherichia coli; Female; Humans; Klebsiella oxytoca; Klebsiella pneumoniae; Male; Middle Aged; Retrospective Studies; Urinary Tract Infections | 2016 |
Colistin- and Carbapenem-Resistant Escherichia coli Harboring mcr-1 and blaNDM-5, Causing a Complicated Urinary Tract Infection in a Patient from the United States.
Topics: Aged; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Colistin; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Humans; Male; Plasmids; Sequence Analysis, DNA; Sequence Homology; Travel; United States; Urinary Tract Infections; Urine | 2016 |
ST147 NDM-1-producing Klebsiella pneumoniae spread in two Tunisian hospitals.
Topics: Adult; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Female; Hospitals; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Middle Aged; Retrospective Studies; Tunisia; Urinary Tract Infections; Young Adult | 2017 |
Carbapenem-Resistant Klebsiella pneumoniae influences the outcome of early infections in liver transplant recipients.
Topics: Adult; Aged; Anti-Bacterial Agents; Carbapenems; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Humans; Italy; Klebsiella Infections; Klebsiella pneumoniae; Liver Transplantation; Male; Middle Aged; Mycoses; Retrospective Studies; Risk Factors; Surgical Wound Infection; Urinary Tract Infections | 2016 |
A prospective study of treatment of carbapenem-resistant Enterobacteriaceae infections and risk factors associated with outcome.
Topics: Adult; Age Factors; Aged; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cohort Studies; Colistin; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Hospital Mortality; Humans; Kidney Failure, Chronic; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia; Polymerase Chain Reaction; Prospective Studies; Renal Dialysis; Risk Factors; Shock, Septic; Urinary Tract Infections | 2016 |
Clinical Experience of Patients Receiving Doripenem-Containing Regimens for the Treatment of Healthcare-Associated Infections.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; APACHE; Carbapenems; Cross Infection; Doripenem; Female; Hospital Mortality; Humans; Intraabdominal Infections; Male; Middle Aged; Respiratory Tract Infections; Retrospective Studies; Soft Tissue Infections; Tertiary Care Centers; Treatment Outcome; Urinary Tract Infections | 2016 |
Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia-Pacific countries: SMART 2013-2015.
Topics: Acinetobacter baumannii; Amikacin; Anti-Infective Agents; Asia; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacter; Ertapenem; Gram-Negative Bacteria; Hospitalization; Humans; Imipenem; Intraabdominal Infections; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Urinary Tract Infections | 2017 |
Prospective study analyzing risk factors and characteristics of healthcare-associated infections in a Urology ward.
Topics: Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Catheters, Indwelling; Cross Infection; Cystectomy; Drug Resistance, Microbial; Enterococcus; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Hospital Units; Humans; Immunosuppression Therapy; Incidence; Klebsiella; Klebsiella Infections; Male; Middle Aged; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Surgical Wound Infection; Urinary Catheters; Urinary Tract Infections; Urology; Vancomycin | 2017 |
Outbreak of carbapenem-resistant Providencia rettgeri in a tertiary hospital.
Topics: Adult; Carbapenems; Coinfection; Cross Infection; Disease Outbreaks; Drug Resistance, Bacterial; Enterobacteriaceae Infections; Female; HIV Infections; Humans; Male; Microbial Sensitivity Tests; Pressure Ulcer; Providencia; South Africa; Tertiary Care Centers; Urinary Tract Infections; Wound Infection | 2016 |
Epidemiology and susceptibility of pathogens from SMART 2011-12 Turkey: evaluation of hospital-acquired versus community-acquired urinary tract infections and ICU- versus non-ICU-associated intra-abdominal infections.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cefoxitin; Community-Acquired Infections; Cross Infection; Enterobacteriaceae; Ertapenem; Escherichia coli; Humans; Imipenem; Intensive Care Units; Intraabdominal Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Turkey; Urinary Tract Infections | 2017 |
Extended spectrum beta lactamase producing organisms causing urinary tract infections in Sri Lanka and their antibiotic susceptibility pattern -A hospital based cross sectional study.
Topics: Anti-Infective Agents; beta-Lactamases; Carbapenems; Cross Infection; Cross-Sectional Studies; Escherichia coli; Escherichia coli Infections; Female; Hospitals, Teaching; Humans; Incidence; Klebsiella; Klebsiella Infections; Male; Microbial Sensitivity Tests; Middle Aged; Prevalence; Sri Lanka; Urinary Tract Infections | 2017 |
Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing Klebsiella pneumoniae.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Carbapenems; Catheter-Related Infections; Female; Greece; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Middle Aged; Prospective Studies; Salvage Therapy; Thienamycins; Treatment Outcome; Urinary Tract Infections; Young Adult | 2017 |
[Antimicrobial activity of tebipenem against various clinical isolates from various specimen, mainly urinary tract].
Topics: Carbapenems; Citrobacter freundii; Drug Resistance, Bacterial; Enterobacter; Enterococcus faecalis; Escherichia coli; Humans; Klebsiella pneumoniae; Urinary Tract Infections | 2009 |
Recurrent healthcare-associated community-onset infections due to Klebsiella pneumoniae producing VIM-1 metallo-beta-lactamase.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Community-Acquired Infections; Cross Infection; Electrophoresis, Gel, Pulsed-Field; Female; Greece; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Plasmids; Polymerase Chain Reaction; Recurrence; Sequence Analysis, DNA; Urinary Tract Infections | 2010 |
Antimicrobial activity of doripenem and other carbapenems against gram-negative pathogens from Korea.
Topics: Anti-Bacterial Agents; Bacteremia; Carbapenems; Doripenem; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Korea; Meropenem; Microbial Sensitivity Tests; Republic of Korea; Thienamycins; Urinary Tract Infections | 2011 |
Detection of CTX-M-15-producing and carbapenem-resistant Acinetobacter baumannii strains from urine from an Indian hospital.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Conjugation, Genetic; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; India; Integrons; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Urinary Tract Infections; Urine | 2010 |
Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Fosfomycin; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Urinary Tract Infections; Young Adult | 2010 |
New Delhi metallo-β-lactamase and multidrug resistance: a global SOS?
Topics: Anti-Bacterial Agents; Australia; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Female; Humans; India; Klebsiella Infections; Klebsiella pneumoniae; Urinary Tract Infections | 2011 |
Carbapenem resistance in Klebsiella pneumoniae due to the New Delhi Metallo-β-lactamase.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Australia; Bacterial Typing Techniques; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Female; Humans; India; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Multilocus Sequence Typing; Urinary Tract Infections | 2011 |
New Delhi metallo-beta-lactamase, Ontario, Canada.
Topics: Adult; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Canada; Carbapenems; Female; Humans; India; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Ontario; Travel; Urinary Tract Infections | 2011 |
Community-acquired carbapenem-resistant Acinetobacter baumannii urinary tract infection just after marriage in a renal transplant recipient.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; beta-Lactam Resistance; Carbapenems; Community-Acquired Infections; Female; Humans; Kidney Transplantation; Marriage; Microbial Sensitivity Tests; Postoperative Complications; Urinary Tract Infections | 2011 |
[Molecular characterization of carbapenemases in Pseudomonas aeruginosa infection. Clinical study in three oncological patients].
Topics: Aged; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Breast Neoplasms; Carbapenems; Carcinoma, Ductal, Breast; Carcinoma, Renal Cell; Cross Infection; Drug Resistance, Multiple, Bacterial; Female; Humans; Immunocompromised Host; Kidney Neoplasms; Laryngeal Neoplasms; Male; Multiple Myeloma; Postoperative Complications; Pseudomonas aeruginosa; Pseudomonas Infections; Urinary Bladder Neoplasms; Urinary Tract Infections | 2011 |
Klebsiella pneumoniae: development of a mixed population of carbapenem and tigecycline resistance during antimicrobial therapy in a kidney transplant patient.
Topics: Aged; Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; beta-Lactamases; Carbapenems; Chromosome Mapping; Cross Infection; Drug Resistance, Multiple, Bacterial; Humans; Kidney Transplantation; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Minocycline; Sequence Analysis, DNA; Tigecycline; Urinary Tract Infections | 2012 |
Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Cohort Studies; Drug Resistance, Bacterial; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Minocycline; Polymyxin B; Retrospective Studies; Tigecycline; Treatment Outcome; Urinary Tract Infections; Urine; Young Adult | 2011 |
Isolation of a Klebsiella pneumoniae isolate of sequence type 258 producing KPC-2 carbapenemase in Korea.
Topics: Aged; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Female; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Republic of Korea; Sequence Analysis, DNA; Urinary Tract Infections | 2011 |
Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; beta-Lactamases; beta-Lactams; Carbapenems; Cefoxitin; Ceftriaxone; Conjugation, Genetic; Disease Models, Animal; Drug Administration Schedule; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Humans; Imipenem; Kidney; Mice; Microbial Sensitivity Tests; Mutation Rate; Plasmids; Urinary Bladder; Urinary Tract Infections | 2012 |
NDM-4 metallo-β-lactamase with increased carbapenemase activity from Escherichia coli.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cephalosporins; Cloning, Molecular; DNA, Bacterial; Escherichia coli; Humans; Hydrolysis; Kinetics; Microbial Sensitivity Tests; Plasmids; Polymerase Chain Reaction; Urinary Tract Infections | 2012 |
Prevalence of antibiotic resistance among Acinetobacter baumannii isolates from Aleppo, Syria.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adolescent; Adult; Anti-Bacterial Agents; Carbapenems; Child; Child, Preschool; Colistin; Drug Resistance, Multiple, Bacterial; Humans; Infant; Microbial Sensitivity Tests; Prevalence; Respiratory Tract Infections; Retrospective Studies; Syria; Urinary Tract Infections; Young Adult | 2012 |
Development of carbapenem resistance during therapy for non-typhoid Salmonella infection.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Ertapenem; Feces; Female; Humans; Microbial Sensitivity Tests; Plasmids; Point Mutation; Porins; RNA, Bacterial; Salmonella Infections; Salmonella typhimurium; Urinary Tract Infections; Wound Infection | 2012 |
Urinary tract infection caused by carbapenem-resistant K. pneumoniae and P. aeruginosa.
Topics: Aged; Anastomosis, Surgical; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Colistin; Drug Resistance, Multiple, Bacterial; Enterobacter cloacae; Enterobacteriaceae Infections; Humans; Infection Control; Klebsiella Infections; Klebsiella pneumoniae; Male; Nephrolithiasis; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms; Urinary Tract Infections | 2011 |
Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART).
Topics: Amikacin; Anti-Bacterial Agents; Asia; Australasia; beta-Lactamases; beta-Lactams; Carbapenems; Ceftazidime; Drug Resistance, Bacterial; Ertapenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prevalence; Prospective Studies; Urinary Tract Infections | 2012 |
Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms.
Topics: Aged; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Drug Resistance, Multiple, Bacterial; Enterococcus faecium; Female; Fosfomycin; Humans; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Retrospective Studies; Treatment Outcome; Urinary Tract Infections | 2012 |
The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Topics: Aged; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefmetazole; Culture Media; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Humans; Male; Microbial Sensitivity Tests; Pyelonephritis; Retrospective Studies; Treatment Outcome; Urinary Tract Infections; Urine | 2013 |
Increasing prevalence of ciprofloxacin resistance in extended-spectrum-β-lactamase-producing Escherichia coli urinary isolates.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Ciprofloxacin; Contraindications; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Fosfomycin; Humans; Male; Middle Aged; Nitrofurantoin; Prevalence; Retrospective Studies; Treatment Failure; Treatment Outcome; Urinary Tract; Urinary Tract Infections; Young Adult | 2013 |
Nosocomial infections caused by multidrug-resistant isolates of pseudomonas putida producing VIM-1 metallo-beta-lactamase.
Topics: Aged; beta-Lactamases; beta-Lactams; Carbapenems; Cross Infection; Drug Resistance, Multiple, Bacterial; Humans; Integrons; Microbial Sensitivity Tests; Middle Aged; Molecular Sequence Data; Pseudomonas Infections; Pseudomonas putida; Urinary Tract Infections | 2002 |
[beta-Lactam antibiotics].
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; Carbapenems; Cephalosporins; Endocarditis, Bacterial; Humans; Molecular Structure; Monobactams; Neutropenia; Penicillins; Respiratory Tract Infections; Soft Tissue Infections; Staphylococcal Skin Infections; Urinary Tract Infections | 2003 |
Characterization of Pseudomonas aeruginosa isolates from patients with urinary tract infections during antibiotic therapy.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Carbapenems; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Electrophoresis, Polyacrylamide Gel; Female; Genotype; Gynecologic Surgical Procedures; Humans; Microbial Sensitivity Tests; Middle Aged; Mutation; Postoperative Complications; Pseudomonas aeruginosa; Pseudomonas Infections; Random Amplified Polymorphic DNA Technique; Treatment Outcome; Urinary Tract Infections | 2003 |
Effect of siliconized latex urinary catheters on the activity of carbapenems against Pseudomonas aeruginosa strains with defined mutations in ampC, oprD, and genes coding for efflux systems.
Topics: Anti-Infective Agents; Bacterial Proteins; beta-Lactamases; Biofilms; Carbapenems; Drug Resistance, Bacterial; Genes, Bacterial; Humans; In Vitro Techniques; Latex; Microbial Sensitivity Tests; Mutation; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Silicones; Urinary Catheterization; Urinary Tract Infections | 2003 |
An outbreak of carbapenem-resistant Pseudomonas aeruginosa in a urology ward.
Topics: Anti-Bacterial Agents; Carbapenems; Cross Infection; Disease Outbreaks; DNA, Bacterial; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Equipment Contamination; Female; Humans; Infection Control; Male; Middle Aged; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Spain; Urinary Tract Infections | 2003 |
[Carbapenems for septicemia. Seeking safe and effective treatment].
Topics: Carbapenems; Humans; Respiratory Tract Infections; Safety; Sepsis; Urinary Tract Infections | 2004 |
Mechanisms of resistance to fluoroquinolones and carbapenems in Pseudomonas putida.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mutation; Pseudomonas putida; Urinary Tract Infections | 2005 |
Emergence of metallo-beta-lactamase producing Pseudomonas aeruginosa in Pakistan.
Topics: beta-Lactam Resistance; beta-Lactamases; Carbapenems; Humans; Male; Middle Aged; Pakistan; Pseudomonas aeruginosa; Urinary Tract Infections | 2005 |
[Antimicrobial susceptibilities of organisms isolated from patients with urinary tract infections in 2002].
Topics: Anti-Bacterial Agents; Carbapenems; Drug Resistance, Bacterial; Enterobacteriaceae; Enterococcus; Enterococcus faecalis; Escherichia coli; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Humans; Pseudomonas aeruginosa; Staphylococcus; Staphylococcus aureus; Urinary Tract Infections | 2006 |
The impact of an antibiotic cycling program on empirical therapy for gram-negative infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactams; Carbapenems; Cephalosporins; Cross Infection; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Resistance, Multiple; Empiricism; Female; Fluoroquinolones; Gram-Negative Bacterial Infections; Hospitals, Teaching; Humans; Intensive Care Units; Male; Middle Aged; Missouri; Penicillins; Pneumonia, Bacterial; Prospective Studies; Survival Rate; Urinary Tract Infections; Ventilators, Mechanical | 2006 |
[A case of urinary tract infection caused by Flavimonas oryzihabitans].
Topics: Anti-Infective Agents, Urinary; Bacteriuria; Carbapenems; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Humans; Middle Aged; Ofloxacin; Pseudomonas; Pseudomonas Infections; Rectal Neoplasms; Renal Insufficiency; Urinary Tract Infections | 2007 |
Are beta-lactams related to higher morbidity and mortality in urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli?
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Escherichia coli; Escherichia coli Infections; Hong Kong; Humans; Retrospective Studies; Treatment Outcome; Urinary Tract Infections | 2008 |
Doripenem (Doribax)--a new parenteral carbapenem.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Carbapenems; Doripenem; Drug Administration Schedule; Drug Interactions; Humans; Infusions, Intravenous; Pneumonia, Ventilator-Associated; Treatment Outcome; Urinary Tract Infections | 2008 |
Acute bacterial prostatitis after transrectal prostate needle biopsy: clinical analysis.
Topics: Aged; Anti-Bacterial Agents; Biopsy, Needle; Blood; Carbapenems; Cephalosporins; Drug Resistance, Bacterial; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Prostate; Prostatitis; Ultrasound, High-Intensity Focused, Transrectal; Urinary Tract Infections; Urine | 2008 |
Doripenem (doribax)--a new parenteral carbapenem.
Topics: Carbapenems; Cross Infection; Doripenem; Female; Humans; Pneumonia; Pneumonia, Ventilator-Associated; Urinary Tract Infections | 2008 |
Sensitivities to four carbapenems of bacteria isolated from patients with refractory complicated urinary tract infections and the detection of carbapenemase-producing Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Thienamycins; Urinary Tract Infections | 1996 |
Comparison of postantibiotic effects of imipenem and netilmicin alone and in combination against Pseudomonas aeruginosa.
Topics: Carbapenems; Drug Therapy, Combination; Gentamicins; Humans; Imipenem; Microbial Sensitivity Tests; Netilmicin; Pseudomonas aeruginosa; Pseudomonas Infections; Urinary Tract Infections | 1997 |
Gram-negative bacilli isolated from patients in intensive care unit: prevalence and antibiotic susceptibility.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Blood; Carbapenems; Cephalosporins; Ciprofloxacin; Cross Infection; Drug Resistance, Microbial; Gram-Negative Bacteria; Humans; Imipenem; Intensive Care Units; Microbial Sensitivity Tests; Respiratory Tract Infections; Saudi Arabia; Urinary Tract Infections; Wounds and Injuries | 1997 |
Carbapenem-hydrolysing beta-lactamase from clinical isolates of Pseudomonas aeruginosa in Portugal.
Topics: Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Humans; Imipenem; Portugal; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Thienamycins; Urinary Tract Infections | 1999 |
Urinary tract infection in neurogenic bladder.
Topics: Acute Disease; Anti-Infective Agents, Urinary; Carbapenems; Cephalosporins; Chronic Disease; Epididymitis; Escherichia coli Infections; Female; Fever; Gram-Negative Bacterial Infections; Humans; Klebsiella Infections; Male; Prostatitis; Pseudomonas Infections; Pyelonephritis; Urinary Bladder; Urinary Bladder, Neurogenic; Urinary Catheterization; Urinary Tract Infections | 2001 |
[Forum of carbapenem antibiotics(discussion)].
Topics: Animals; Bacteria; Carbapenems; Clinical Trials as Topic; Drug Resistance, Microbial; Humans; Pseudomonas aeruginosa; Respiratory Tract Infections; Streptococcus pneumoniae; Treatment Outcome; Urinary Tract Infections | 2001 |
In vitro antibacterial activity of S-4661, a new parenteral carbapenem, against urological pathogens isolated from patients with complicated urinary tract infections.
Topics: Anti-Bacterial Agents; Bacteria; Carbapenems; Ceftazidime; Doripenem; Humans; Imipenem; In Vitro Techniques; Meropenem; Microbial Sensitivity Tests; Thienamycins; Urinary Tract Infections | 2002 |
[Current chemotherapy in urogenital infections. Part 5:Macrolide antibiotics, carbapenems, monobactams, beta-lactamase inhibitors].
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Female Urogenital Diseases; Humans; Macrolides; Male Urogenital Diseases; Microbial Sensitivity Tests; Monobactams; Urinary Tract Infections | 1992 |
Therapeutic activity of meropenem in experimental infections.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Escherichia coli Infections; Guinea Pigs; Immunosuppression Therapy; Lung Diseases; Male; Meropenem; Mice; Mice, Inbred Strains; Microbial Sensitivity Tests; Pseudomonas Infections; Respiratory Tract Infections; Thienamycins; Urinary Tract Infections | 1989 |